Tag Archives: EXEL

Top 10 High Tech Stocks To Buy For 2019

&l;p style=&q;background: white&q;&g;&l;span style=&q;color: black&q;&g;By Juan Pereira and Jonathan Carmody&l;/span&g;&l;/p&g;

Infrastructure fundraising in Mexico picked up rapidly in 2018, according to stock exchange filings and the government website &l;a href=&q;https://www.proyectosmexico.gob.mx/en/home/&q; target=&q;_blank&q;&g;Proyectos Mexico&l;/a&g;.

Both the number of new funds and the amount raised reached record highs last year. Fundraising in Mexico picked up rapidly in 2018, with fundraising of new and previous funds 38.5% higher than in 2017 and more than double compared to 2016.

But how these funds will be allocated is open to question given the context of cancellations and delays in project procurement by the new presidential administration, such as the $13 billion Mexico City airport project.

Of the 26 large infrastructure and energy funds (&l;a href=&q;https://www2.deloitte.com/content/dam/Deloitte/mx/Documents/tax/FIBRA-E-Tax-Eng.pdf&q; target=&q;_blank&q;&g;Certificates of Capital Development &a;ndash;CKD&a;ndash; and Certificates of Project Investment &a;ndash;CERPI&a;ndash;&l;/a&g;) launched in Mexico, eight were launched in 2018, with over $420 million of capital raised. In 2018, for the first time, more CERPIs were launched than CKDs.

Top 10 High Tech Stocks To Buy For 2019: Eaton Vance Short Diversified Income Fund(EVG)

Advisors’ Opinion:

  • [By Stephan Byrd]

    EATON VANCE SHO/COM (NYSE:EVG) declared a monthly dividend on Thursday, September 6th, Wall Street Journal reports. Investors of record on Friday, September 21st will be paid a dividend of 0.065 per share on Friday, September 28th. This represents a $0.78 dividend on an annualized basis and a yield of 6.06%. The ex-dividend date is Thursday, September 20th.

Top 10 High Tech Stocks To Buy For 2019: Exelixis, Inc.(EXEL)

Advisors’ Opinion:

  • [By Brian Orelli]

    Shares of Exelixis (NASDAQ:EXEL) are down 12% at 2:02 p.m. EDT after announcing the IMblaze370 phase 3 trial testing its Cotellic with Roche’s Tecentriq failed to improve overall survival compared to Bayer’s Stivarga in patients with locally advanced or metastatic colorectal cancer.

  • [By ]

    Cramer was bearish on Xilinx (XLNX) , Celgene (CELG) , Exelixis (EXEL) , Moneygram (MGI) , Monster Beverage (MNST) , SunCoke Energy Partners (SXCP) and Mattel (MAT) .

  • [By Ethan Ryder]

    Rhumbline Advisers boosted its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 87.7% in the second quarter, HoldingsChannel.com reports. The firm owned 593,969 shares of the biotechnology company’s stock after purchasing an additional 277,533 shares during the quarter. Rhumbline Advisers’ holdings in Exelixis were worth $12,782,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

  • [By Max Byerly]

    In other news, CEO Michael Morrissey sold 6,046 shares of Exelixis stock in a transaction that occurred on Wednesday, January 2nd. The shares were sold at an average price of $20.00, for a total value of $120,920.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Alan M. Garber sold 11,250 shares of Exelixis stock in a transaction that occurred on Tuesday, January 8th. The stock was sold at an average price of $23.00, for a total transaction of $258,750.00. Following the completion of the transaction, the director now directly owns 72,579 shares in the company, valued at $1,669,317. The disclosure for this sale can be found here. Insiders sold a total of 381,807 shares of company stock worth $8,003,832 in the last ninety days. Corporate insiders own 4.80% of the company’s stock.

    TRADEMARK VIOLATION WARNING: “Arizona State Retirement System Acquires 2,972 Shares of Exelixis, Inc. (EXEL)” was originally posted by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright legislation. The original version of this article can be viewed at https://www.tickerreport.com/banking-finance/4126422/arizona-state-retirement-system-acquires-2972-shares-of-exelixis-inc-exel.html.

    Exelixis Profile

Top 10 High Tech Stocks To Buy For 2019: Barclays PLC(BCS)

Advisors’ Opinion:

  • [By Logan Wallace]

    Barclays (NYSE:BCS) and First Republic Bank (NYSE:FRC) are both large-cap finance companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, risk, earnings, dividends, valuation, profitability and analyst recommendations.

  • [By Matthew Frankel]

    Apple (NASDAQ:AAPL) is teaming up with investment banking giant Goldman Sachs (NYSE:GS) to develop and launch a new co-branded credit card next year, according to a report in the Wall Street Journal. This would replace the tech giant’s current partnership with Barclays (NYSE:BCS), and would be issued under the Apple Pay brand name.

  • [By Joseph Griffin]

    Barclays PLC (NYSE:BCS) major shareholder Plc Barclays sold 62,390 shares of the business’s stock in a transaction dated Thursday, June 28th. The shares were sold at an average price of $5.63, for a total value of $351,255.70. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Top 10 High Tech Stocks To Buy For 2019: Express-1 Expedited Solutions Inc.(XPO)

Advisors’ Opinion:

  • [By Logan Wallace]

    GATX (NYSE: XPO) and XPO Logistics (NYSE:XPO) are both transportation companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

  • [By Rich Duprey, Nicholas Rossolillo, and Maxx Chatsko]

    We asked three Motley Fool investors to identify a company they consider to be much a better value than digital money. They chose salesforce.com (NYSE:CRM), Zoetis (NYSE:ZTS), and XPO Logistics (NYSE:XPO) as the top alternatives to any cryptocurrency available. 

  • [By Logan Wallace]

    XPO Logistics (NYSE:XPO)‘s stock had its “buy” rating reissued by research analysts at Bank of America in a research note issued on Friday. They presently have a $105.00 target price on the transportation company’s stock. Bank of America’s price objective would indicate a potential upside of 4.86% from the stock’s previous close.

  • [By Dan Caplinger]

    Friday was a good day on Wall Street, as positive news on the domestic political front spurred market participants to send stock benchmarks to substantial gains. Earnings season has reached its peak, but overall, investors have been a lot more comfortable with the idea that sustained economic growth could last further into 2019 than they were during the stock market’s swoon in December. Nevertheless, not every company was able to find success during a tough period. Newell Brands (NYSE:NWL), TrueCar (NASDAQ:TRUE), and XPO Logistics (NYSE:XPO) were among the worst performers. Here’s why they did so poorly.

Top 10 High Tech Stocks To Buy For 2019: First Busey Corporation(BUSE)

Advisors’ Opinion:

  • [By Ethan Ryder]

    BidaskClub downgraded shares of First Busey (NASDAQ:BUSE) from a buy rating to a hold rating in a research report sent to investors on Saturday morning.

  • [By Stephan Byrd]

    Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp bought a new stake in shares of First Busey Co. (NASDAQ:BUSE) during the 1st quarter, Holdings Channel reports. The firm bought 7,000 shares of the bank’s stock, valued at approximately $208,000.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on First Busey (BUSE)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    Get a free copy of the Zacks research report on First Busey (BUSE)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    Shares of First Busey Co. (NASDAQ:BUSE) hit a new 52-week high and low during trading on Monday . The company traded as low as $33.22 and last traded at $32.70, with a volume of 1006 shares traded. The stock had previously closed at $33.00.

Top 10 High Tech Stocks To Buy For 2019: NetSol Technologies Inc.(NTWK)

Advisors’ Opinion:

  • [By Stephan Byrd]

    TheStreet upgraded shares of NetSol Technologies (NASDAQ:NTWK) from a d+ rating to a c- rating in a research note published on Tuesday morning.

    Separately, ValuEngine raised shares of NetSol Technologies from a hold rating to a buy rating in a research report on Thursday, May 17th.

  • [By Lisa Levin] Gainers
    Precipio, Inc. (NASDAQ: PRPO) jumped 43.3 percent to $0.5447 after the micro-cap specialty diagnostics company reported preliminary first-quarter results. The company said its first quarter revenue rose 286 percent from the same quarter a year ago to $712,000.
    Galectin Therapeutics, Inc. (NASDAQ: GALT) gained 34.5 percent to $4.52 after the company announced it would proceed with Phase 3 development of GR-MD-02 for NASH Cirrhosis following the FDA meeting.
    Boxlight Corporation (NASDAQ: BOXL) shares rose 21.9 percent to $8.1063.
    Evolus, Inc. (NASDAQ: EOLS) shares surged 16 percent to $15.65.
    Myomo, Inc. (NYSE: MYO) shares jumped 15.5 percent to $3.6263 after the company disclosed that its application for Medicare codes received favorable preliminary decision.
    Tandem Diabetes Care, Inc. (NASDAQ: TNDM) rose 13.7 percent to $10.12.
    ProPhase Labs, Inc. (NASDAQ: PRPH) gained 13.7 percent to $4.6743.
    Acacia Communications, Inc. (NASDAQ: ACIA) shares gained 12.2 percent to $35.34 as optical sector is seeing strength following President Trump's announcement that he would work with China related to ZTE Corp.
    Tailored Brands, Inc. (NYSE: TLRD) shares rose 11.3 percent to $35.17. Jefferies upgraded Tailored Brands from Hold to Buy.
    Kona Grill, Inc. (NASDAQ: KONA) jumped 10.6 percent to $2.875.
    Federated National Holding Company (NASDAQ: FNHC) shares rose 10.6 percent to $20.29. Raymond James upgraded Federated National Holding from Outperform to Strong Buy.
    Renewable Energy Group, Inc. (NASDAQ: REGI) climbed 10.2 percent to $15.15. Renewable Energy will replace Synchronoss Technologies Inc. (NASDAQ: SNCR) in the S&P SmallCap 600 on Tuesday, May 15.
    Stein Mart, Inc. (NASDAQ: SMRT) shares climbed 10.1 percent to $3.16. Stein Mart is expected to release Q1 earnings on May 23.
    NXP Semiconductors N.V. (NASDAQ: NXPI) rose 9.7 percent to $108.60 after Bloomberg reported that the China’s Commerce Ministry has restar
  • [By Logan Wallace]

    Sapiens International (NASDAQ: SPNS) and NetSol Technologies (NASDAQ:NTWK) are both small-cap computer and technology companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends and risk.

  • [By Stephan Byrd]

    NetSol Technologies (NASDAQ:NTWK) CEO Najeeb Ghauri acquired 2,500 shares of NetSol Technologies stock in a transaction that occurred on Wednesday, May 30th. The stock was acquired at an average price of $6.50 per share, with a total value of $16,250.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

  • [By Ethan Ryder]

    NetSol Technologies (NASDAQ:NTWK) CEO Najeeb Ghauri purchased 2,500 shares of the business’s stock in a transaction on Friday, May 25th. The shares were acquired at an average cost of $6.20 per share, with a total value of $15,500.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Top 10 High Tech Stocks To Buy For 2019: ASML Holding N.V.(ASML)

Advisors’ Opinion:

  • [By Max Byerly]

    Front Row Advisors LLC increased its holdings in ASML Holding NV (NASDAQ:ASML) by 15.5% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,247 shares of the semiconductor company’s stock after purchasing an additional 703 shares during the period. Front Row Advisors LLC’s holdings in ASML were worth $1,042,000 as of its most recent SEC filing.

  • [By Billy Duberstein]

    Looking for higher growth but also a bit of yield? European semiconductor equipment maker ASML (NASDAQ:ASML) is an exciting story. ASML has a dividend yield of just 0.94%, but good things can come in small packages. Last year, ASML hiked that payout by 50%, and it has increased its dividend tenfold over the past 10 years. In addition, that current payout is well covered by just a 23.2% payout ratio.

  • [By Dan Caplinger]

    The stock market didn’t see much in the way of sustained movement Wednesday, with the major market indexes finished mixed, but close to where they began the day. Various cross-currents pushed shares higher and lower throughout the day, including the potential for a breakthrough on the trade front, and nervousness about the directions of interest rates and monetary policy both in the U.S. and internationally. Weighing on sentiment was bad news from some key individual companies that sent their respective stocks lower. Snap (NYSE:SNAP), Fitbit (NYSE:FIT), and ASML Holding (NASDAQ:ASML) were among the worst performers on the day. Below, we’ll look more closely at these companies to tell you why their shares fared so poorly.

  • [By Stephan Byrd]

    Investec Asset Management LTD purchased a new position in shares of ASML Holding NV (NASDAQ:ASML) during the second quarter, HoldingsChannel reports. The institutional investor purchased 19,841 shares of the semiconductor company’s stock, valued at approximately $3,928,000.

Top 10 High Tech Stocks To Buy For 2019: China Pharma Holdings Inc.(CPHI)

Advisors’ Opinion:

  • [By Logan Wallace]

    These are some of the news headlines that may have impacted Accern Sentiment’s scoring:

    Get Scynexis alerts:

    Steady Activities: SCYNEXIS, Inc. (NASDAQ:SCYX), LPL Financial Holdings Inc. (NASDAQ:LPLA) (oracleexaminer.com) Do Analysts Think You Should Buy – SCYNEXIS Inc (NASDAQ: SCYX) (stockspen.com) Notable Runner: SCYNEXIS, Inc. (SCYX) (nasdaqplace.com) Most Active Stocks Now: SCYNEXIS, Inc. (NASDAQ:SCYX), China Pharma Holdings, Inc. (NYSE:CPHI), Kala … (journalfinance.net) Overview on price to free cash flow: SCYNEXIS, Inc. (NASDAQ:SCYX), InfuSystem Holdings Inc. (NYSE:INFU) (stocksnewspoint.com)

    Several research analysts have recently issued reports on the company. Roth Capital assumed coverage on Scynexis in a research note on Tuesday, May 8th. They set a “buy” rating and a $6.00 price target for the company. Seaport Global Securities assumed coverage on Scynexis in a research note on Tuesday, April 10th. They set a “buy” rating and a $4.00 price target for the company. Zacks Investment Research raised Scynexis from a “hold” rating to a “buy” rating and set a $1.25 price target for the company in a research note on Tuesday, May 8th. HC Wainwright assumed coverage on Scynexis in a research note on Monday, May 7th. They set a “buy” rating and a $5.00 price target for the company. Finally, ValuEngine raised Scynexis from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Scynexis currently has an average rating of “Buy” and an average target price of $4.45.

Top 10 High Tech Stocks To Buy For 2019: Dunkin' Brands Group, Inc.(DNKN)

Advisors’ Opinion:

  • [By Logan Wallace]

    Dunkin’ Brands (NASDAQ:DNKN) CFO Katherine D. Jaspon sold 1,530 shares of the firm’s stock in a transaction on Tuesday, May 8th. The shares were sold at an average price of $64.84, for a total value of $99,205.20. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

  • [By ]

    Dunkin’ Brands Group (DNKN) had little time to celebrate its better than expected first-quarter on Thursday as headlines erupted early that noted short-seller Jim Chanos has bet against the company. Chanos said in a TV interview that he has been short shares of Dunkin’ and Burger King/Tim Horton’s owner Restaurant Brands International (QSR) for about a year. Chanos’ main contention: valuations for the two fast-food heavyweights are too high and he thinks it’s better for restaurants to own their own real estate, rather than franchise. 

  • [By Max Byerly]

    Teacher Retirement System of Texas decreased its position in Dunkin Brands Group Inc (NASDAQ:DNKN) by 16.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 16,685 shares of the restaurant operator’s stock after selling 3,314 shares during the period. Teacher Retirement System of Texas’ holdings in Dunkin Brands Group were worth $1,152,000 as of its most recent SEC filing.

Top 10 High Tech Stocks To Buy For 2019: Cincinnati Financial Corporation(CINF)

Advisors’ Opinion:

  • [By Ethan Ryder]

    WealthPLAN Partners LLC grew its holdings in Cincinnati Financial Co. (NASDAQ:CINF) by 45.5% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 33,842 shares of the insurance provider’s stock after acquiring an additional 10,584 shares during the quarter. WealthPLAN Partners LLC’s holdings in Cincinnati Financial were worth $2,513,000 at the end of the most recent reporting period.

  • [By Joseph Griffin]

    Tibra Equities Europe Ltd purchased a new position in Cincinnati Financial Co. (NASDAQ:CINF) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 11,909 shares of the insurance provider’s stock, valued at approximately $796,000.

  • [By ]

    Insurance company Cincinnati Financial Corporation (Nasdaq: CINF) defied the Great Recession and stayed healthy throughout. The insurance company raised its book value per share by 17 percent in 2017, and even paid a special dividend in late 2017 due to the company’s equity portfolio appreciation exceeding expectations.

  • [By Ethan Ryder]

    Swiss National Bank lowered its holdings in Cincinnati Financial (NASDAQ:CINF) by 13.6% in the first quarter, HoldingsChannel reports. The firm owned 498,032 shares of the insurance provider’s stock after selling 78,400 shares during the quarter. Swiss National Bank’s holdings in Cincinnati Financial were worth $36,984,000 as of its most recent SEC filing.

  • [By Stephan Byrd]

    Cincinnati Financial (NASDAQ:CINF) and Third Point Reinsurance (NYSE:TPRE) are both finance companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends.

Hot Casino Stocks To Buy Right Now

Not many experts would recommend packing investment accounts like 401(k) retirement plans with bitcoin. The digital currency is just too volatile. But there’s nothing wrong with setting a little aside — money you can afford to lose — for wild bets, like gambling a few bucks at a casino.

Mike Segar | Reuters There are two ways to bet on bitcoin: via a specialized exchange, or through buying and selling futures contracts.

Bitcoin certainly offers an adrenaline rush. In 2017 the price of the cryptocurrency soared from less than $1,000 to nearly $20,000, then tumbled to less than $8,000 early this year. It’s just a tad higher today.

Hot Casino Stocks To Buy Right Now: National Commerce Corporation(NCOM)

Advisors’ Opinion:

  • [By Shane Hupp]

    Citigroup Inc. trimmed its holdings in shares of National Commerce Corp (NASDAQ:NCOM) by 44.5% in the first quarter, Holdings Channel reports. The institutional investor owned 2,703 shares of the financial services provider’s stock after selling 2,171 shares during the period. Citigroup Inc.’s holdings in National Commerce were worth $118,000 as of its most recent SEC filing.

  • [By Joseph Griffin]

    The Manufacturers Life Insurance Company boosted its holdings in shares of National Commerce Corp (NASDAQ:NCOM) by 0.8% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 223,067 shares of the financial services provider’s stock after acquiring an additional 1,798 shares during the quarter. The Manufacturers Life Insurance Company owned 1.29% of National Commerce worth $9,714,000 as of its most recent SEC filing.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on National Commerce (NCOM)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    ValuEngine downgraded shares of National Commerce (NASDAQ:NCOM) from a hold rating to a sell rating in a research report released on Thursday.

    NCOM has been the subject of several other reports. BidaskClub upgraded shares of National Commerce from a buy rating to a strong-buy rating in a research report on Thursday, May 31st. Zacks Investment Research upgraded shares of National Commerce from a hold rating to a buy rating and set a $53.00 target price for the company in a research report on Wednesday, June 27th. Finally, Stephens reiterated a hold rating and set a $48.00 target price on shares of National Commerce in a research report on Thursday, July 26th. Two investment analysts have rated the stock with a sell rating and three have given a hold rating to the stock. The company currently has a consensus rating of Hold and an average target price of $48.67.

Hot Casino Stocks To Buy Right Now: Pinnacle Foods, Inc.(PF)

Advisors’ Opinion:

  • [By Jeremy Bowman]

    Shares of Pinnacle Foods Inc. (NYSE:PF) were moving higher in April after the packaged-foods company became a target of activist investor Jana Partners. As a result the stock finished the month up 12%, according to data from S&P Global Market Intelligence. 

  • [By Shane Hupp]

    Here are some of the news articles that may have impacted Accern’s rankings:

    Get Targa Resources alerts:

    Targa Resources: Poised For Strong Performance Due To Permian Growth (seekingalpha.com) Why Targa Resources (TRGP) Could Be Positioned for a Surge (finance.yahoo.com) Intraday Basic Materials Mover: Targa Resources Corp. (TRGP) (stockdigest.info) QI & Technicals in View For Targa Resources Corp. (NYSE:TRGP), Vivint Solar, Inc. (NYSE:VSLR) (vassarnews.com) Stocks Review- Pinnacle Foods Inc. (NYSE:PF), Targa Resources Corp. (NYSE:TRGP), Pinnacle West Capital … (journalfinance.net)

    Several equities analysts have commented on TRGP shares. Zacks Investment Research downgraded shares of Targa Resources from a “buy” rating to a “hold” rating in a research report on Friday, August 24th. ValuEngine raised shares of Targa Resources from a “hold” rating to a “buy” rating in a research report on Saturday, July 14th. UBS Group increased their target price on shares of Targa Resources from $60.00 to $61.00 and gave the stock a “buy” rating in a research report on Friday, August 10th. Seaport Global Securities downgraded shares of Targa Resources from a “buy” rating to a “neutral” rating and increased their target price for the stock from $53.00 to $55.00 in a research report on Friday, July 27th. Finally, Stifel Nicolaus set a $53.00 target price on shares of Targa Resources and gave the stock a “buy” rating in a research report on Friday, May 4th. Twelve equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $56.00.

  • [By Shane Hupp]

    Pinnacle Foods (NYSE:PF) last posted its earnings results on Thursday, May 3rd. The company reported $0.57 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.56 by $0.01. Pinnacle Foods had a net margin of 17.93% and a return on equity of 14.39%. The firm had revenue of $778.83 million for the quarter, compared to analyst estimates of $767.94 million. During the same period in the previous year, the firm posted $0.50 EPS. The company’s revenue for the quarter was up 1.7% compared to the same quarter last year. equities research analysts predict that Pinnacle Foods will post 2.89 EPS for the current year.

  • [By Ethan Ryder]

    Synovus Financial Corp acquired a new stake in shares of Pinnacle Foods (NYSE:PF) in the first quarter, HoldingsChannel reports. The fund acquired 2,094 shares of the company’s stock, valued at approximately $113,000.

  • [By Chris Hill]

    Meanwhile, in the packaged foods arena, ConAgra (NYSE:CAG) is buying Pinnacle Foods (NYSE:PF) in an $11 billion deal. But combining the owner of Birds Eye with the company behind Healthy Choice is a lot less of a power move than it once might have been.

  • [By Motley Fool Staff]

    Plenty of companies out there are less well-known than the brands in their stables. Case in point: It would be understandable if you didn’t know much about either ConAgra (NYSE:CAG) or Pinnacle Foods (NYSE:PF).

Hot Casino Stocks To Buy Right Now: SuperValu Inc.(SVU)

Advisors’ Opinion:

  • [By Lisa Levin]

    Wednesday morning, the consumer staples shares fell by just 0.2 percent. Meanwhile, top gainers in the sector included SUPERVALU Inc. (NYSE: SVU), up 4 percent, and Imperial Brands PLC (OTC: IMBBY), up 2 percent.

  • [By Lisa Levin] Companies Reporting Before The Bell
    United Technologies Corporation (NYSE: UTX) is estimated to report quarterly earnings at $1.51 per share on revenue of $14.62 billion.
    The Coca-Cola Company (NYSE: KO) is expected to report quarterly earnings at $0.46 per share on revenue of $7.31 billion.
    Caterpillar Inc. (NYSE: CAT) is projected to report quarterly earnings at $2.07 per share on revenue of $11.93 billion.
    Verizon Communications Inc. (NYSE: VZ) is expected to report quarterly earnings at $1.11 per share on revenue of $31.22 billion.
    Lockheed Martin Corporation (NYSE: LMT) is estimated to report quarterly earnings at $3.42 per share on revenue of $11.28 billion.
    The Sherwin-Williams Company (NYSE: SHW) is projected to report quarterly earnings at $3.15 per share on revenue of $3.94 billion.
    Biogen Inc. (NASDAQ: BIIB) is expected to report quarterly earnings at $5.92 per share on revenue of $3.15 billion.
    3M Company (NYSE: MMM) is estimated to report quarterly earnings at $2.52 per share on revenue of $8.26 billion.
    JetBlue Airways Corporation (NASDAQ: JBLU) is projected to report quarterly earnings at $0.2 per share on revenue of $1.75 billion.
    Eli Lilly and Company (NYSE: LLY) is expected to report quarterly earnings at $1.13 per share on revenue of $5.49 billion.
    Harley-Davidson, Inc. (NYSE: HOG) is estimated to report quarterly earnings at $0.88 per share on revenue of $1.25 billion.
    Corning Incorporated (NYSE: GLW) is expected to report quarterly earnings at $0.3 per share on revenue of $2.50 billion.
    Centene Corporation (NYSE: CNC) is projected to report quarterly earnings at $1.88 per share on revenue of $13.28 billion.
    The Travelers Companies, Inc. (NYSE: TRV) is estimated to report quarterly earnings at $2.77 per share on revenue of $6.75 billion.
    Wipro Limited (NYSE: WIT) is expected to report quarterly earnings at $0.07 per share on revenue of $2.16 billion.
    PACCAR Inc (NASDAQ: PCAR) is projected to
  • [By Brian Stoffel]

    But over the past five years, the industry has been turned upside down by changes in business models, a focus on delivery, and mass consolidation. While the dust is far from settled, here are 10 of the largest publicly traded grocers you can buy stock in.

    Company Market Cap Stores Regions Chains
    Amazon (NASDAQ:AMZN) $780 billion 500 USA Whole Foods
    Walmart (NYSE:WMT) $250 billion 11,700 Worldwide Walmart
    Costco (NASDAQ:COST) $86 billion 750 USA Costco
    Kroger (NYSE:KR) $21 billion 2,800 USA Kroger, Roundy’s, Ralph’s, Food 4 Less
    Sprouts (NASDAQ: SFM) $3 billion 300 Western and Southern U.S. Sprouts Farmer’s Market
    Weis Market (NYSE: WMK) $1.3 billion 200 Mid-Atlantic U.S. Weis Market
    SUPERVALU (NYSE: SVU) $630 million 100 Midwestern U.S. Cub Foods, Shopper’s Food, Hornbacher
    Ingles Market (NASDAQ: IMKTA) $580 million 200 Southeastern U.S. Ingles Market, Sav-Mor
    Smart & Final (NYSE: SFS) $360 million 350 Western U.S. Smart & Final, Cash & Carry
    Natural Grocers (NYSE: NGVC) $230 million 150 Western U.S. Natural Grocers

    Data source: Yahoo! Finance, company websites.

Hot Casino Stocks To Buy Right Now: Masco Corporation(MAS)

Advisors’ Opinion:

  • [By ]

    Masco (MAS) : “I like Masco. We have a housing shortage and that’s good for Masco.”

    Over on Real Money, Cramer says the Netflix  (NFLX) numbers show that cord-cutting is more than palpable. Get more of his insights with a free trial subscription to Real Money.

  • [By Logan Wallace]

    ValuEngine downgraded shares of Masco (NYSE:MAS) from a hold rating to a sell rating in a research note published on Tuesday.

    MAS has been the subject of several other reports. Royal Bank of Canada set a $46.00 price objective on shares of Masco and gave the company a buy rating in a research report on Friday, February 9th. Credit Suisse Group reaffirmed a neutral rating and issued a $46.00 price objective (up from $36.00) on shares of Masco in a research report on Monday, January 22nd. They noted that the move was a valuation call. Gabelli raised shares of Masco from a hold rating to a buy rating and set a $51.00 price objective for the company in a research report on Wednesday, April 25th. Bank of America lowered shares of Masco from a buy rating to a neutral rating and decreased their price objective for the company from $46.45 to $35.79 in a research report on Monday, May 14th. Finally, Zacks Investment Research lowered shares of Masco from a buy rating to a hold rating in a research report on Tuesday, March 6th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and thirteen have given a buy rating to the stock. Masco presently has a consensus rating of Buy and an average price target of $44.75.

  • [By Stephan Byrd]

    Symphony Asset Management LLC cut its stake in shares of Masco Corp (NYSE:MAS) by 51.9% in the first quarter, HoldingsChannel.com reports. The fund owned 38,006 shares of the construction company’s stock after selling 41,020 shares during the period. Symphony Asset Management LLC’s holdings in Masco were worth $1,537,000 at the end of the most recent reporting period.

Hot Casino Stocks To Buy Right Now: Exelixis, Inc.(EXEL)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Wedbush Securities Inc. purchased a new position in shares of Exelixis (NASDAQ:EXEL) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 14,215 shares of the biotechnology company’s stock, valued at approximately $315,000.

  • [By Shane Hupp]

    Old Mutual Global Investors UK Ltd. raised its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 26.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,562,369 shares of the biotechnology company’s stock after purchasing an additional 747,398 shares during the quarter. Old Mutual Global Investors UK Ltd. owned 1.20% of Exelixis worth $78,906,000 as of its most recent SEC filing.

  • [By Max Byerly]

    In other news, CEO Michael Morrissey sold 6,046 shares of Exelixis stock in a transaction that occurred on Wednesday, January 2nd. The shares were sold at an average price of $20.00, for a total value of $120,920.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Alan M. Garber sold 11,250 shares of Exelixis stock in a transaction that occurred on Tuesday, January 8th. The stock was sold at an average price of $23.00, for a total transaction of $258,750.00. Following the completion of the transaction, the director now directly owns 72,579 shares in the company, valued at $1,669,317. The disclosure for this sale can be found here. Insiders sold a total of 381,807 shares of company stock worth $8,003,832 in the last ninety days. Corporate insiders own 4.80% of the company’s stock.

    TRADEMARK VIOLATION WARNING: “Arizona State Retirement System Acquires 2,972 Shares of Exelixis, Inc. (EXEL)” was originally posted by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright legislation. The original version of this article can be viewed at https://www.tickerreport.com/banking-finance/4126422/arizona-state-retirement-system-acquires-2972-shares-of-exelixis-inc-exel.html.

    Exelixis Profile

  • [By Ethan Ryder]

    Exelixis (NASDAQ:EXEL) – Investment analysts at William Blair raised their FY2018 earnings per share (EPS) estimates for shares of Exelixis in a research report issued to clients and investors on Thursday, May 3rd. William Blair analyst A. Hsieh now anticipates that the biotechnology company will post earnings per share of $0.90 for the year, up from their previous estimate of $0.66. William Blair currently has a “Buy” rating on the stock. William Blair also issued estimates for Exelixis’ Q1 2019 earnings at $0.23 EPS, Q2 2019 earnings at $0.25 EPS, Q3 2019 earnings at $0.27 EPS and Q4 2019 earnings at $0.29 EPS.

  • [By Stephan Byrd]

    EXEL has been the subject of several recent research reports. ValuEngine lowered Exelixis from a “hold” rating to a “sell” rating in a research report on Saturday, January 19th. BidaskClub lowered Exelixis from a “buy” rating to a “hold” rating in a research report on Saturday, January 19th. Piper Jaffray Companies dropped their price target on Exelixis from $29.00 to $26.00 and set an “overweight” rating for the company in a research report on Monday, November 5th. Oppenheimer set a $40.00 price target on Exelixis and gave the stock a “buy” rating in a research report on Thursday, November 15th. Finally, TheStreet upgraded Exelixis from a “c+” rating to a “b-” rating in a research report on Monday, December 17th. Two research analysts have rated the stock with a sell rating, three have given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $28.38.

    TRADEMARK VIOLATION WARNING: “George A. Scangos Sells 40,000 Shares of Exelixis, Inc. (EXEL) Stock” was reported by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another domain, it was illegally copied and republished in violation of international copyright legislation. The correct version of this article can be accessed at https://www.tickerreport.com/banking-finance/4119260/george-a-scangos-sells-40000-shares-of-exelixis-inc-exel-stock.html.

    About Exelixis

  • [By Motley Fool Transcription]

    Exelixis, Inc. (NASDAQ:EXEL) Q4 2018 Earnings Conference Call Feb. 12, 2019, 5:00 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

Hot Casino Stocks To Buy Right Now: Four Corners Property Trust, Inc.(FCPT)

Advisors’ Opinion:

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Four Corners Property (FCPT)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Shane Hupp]

    Boenning Scattergood set a $30.00 target price on Four Corners Property Trust (NYSE:FCPT) in a research report released on Friday morning. The firm currently has a buy rating on the financial services provider’s stock.

  • [By Joseph Griffin]

    These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:

    Get Four Corners Property Trust alerts:

    FCPT Closes 46 Chili’s Restaurant Properties for $149.8 million as part of Previously Announced Brinker Sale-Leaseback Transaction (finance.yahoo.com) FCPT Announces Acquisition of a Buffalo Wild Wings Restaurant Property for $1.7 million (finance.yahoo.com) Four Corners Property Trust (FCPT) vs. Sutherland Asset Management (SLD) Head to Head Analysis (americanbankingnews.com) FCPT Announces Acquisition of an Arby’s Restaurant Property for $1.6 million (finance.yahoo.com) Four Corners Property Trust Inc (FCPT) Expected to Post Quarterly Sales of $35.62 Million (americanbankingnews.com)

    Shares of Four Corners Property Trust traded down $0.16, hitting $26.01, during trading hours on Friday, according to MarketBeat Ratings. The stock had a trading volume of 360,648 shares, compared to its average volume of 479,703. The company has a current ratio of 6.59, a quick ratio of 6.59 and a debt-to-equity ratio of 0.90. The firm has a market capitalization of $1.65 billion, a P/E ratio of 19.13 and a beta of -0.04. Four Corners Property Trust has a 12-month low of $21.28 and a 12-month high of $26.96.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Four Corners Property Trust (FCPT)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Blue Chip Stocks To Watch Right Now

Sports and stocks go hand in hand.

Wall Street denizens often talk about slam dunk investments and describe the economic cycle as being in a particular inning.

So it makes perfect sense that there’s an ETF dedicated to the business of sports.

The ProSports Sponsors exchange-traded fund, which has the ticker symbol FANZ (FANZ), invests in companies that have business deals with the four major US team sports leagues.

Nick Fullerton, CEO of SportsETFs, the company behind the fund, said it was set up last year to take advantage of the popularity of team sports, which bring in big dollars.

Legal gambling, which is set to spread across the United States, could boost that popularity even more.

Fullerton was quick to point out that the companies in the FANZ ETF must have an actual sponsorship with a major league, and not just a naming rights deal on a stadium.

No CMGIs or Enrons here.

“These are blue chip companies with strong balance sheets and cash flow,” Fullerton said.

Top 10 Blue Chip Stocks To Watch Right Now: Universal Health Services, Inc.(UHS)

Advisors’ Opinion:

  • [By Logan Wallace]

    TheStreet cut shares of Universal Health Services, Inc. Class B (NYSE:UHS) from a b rating to a c+ rating in a research note published on Friday morning.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Universal Health Services, Inc. Class B (UHS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Shane Hupp]

    Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp lifted its stake in shares of Universal Health Services, Inc. Class B (NYSE:UHS) by 4.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 34,800 shares of the health services provider’s stock after acquiring an additional 1,400 shares during the quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp’s holdings in Universal Health Services, Inc. Class B were worth $3,878,000 at the end of the most recent reporting period.

  • [By Max Byerly]

    Parametrica Management Ltd acquired a new stake in Universal Health Services (NYSE:UHS) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,694 shares of the health services provider’s stock, valued at approximately $201,000.

  • [By Stephan Byrd]

    Quorum Health (NYSE: QHC) and Universal Health Services (NYSE:UHS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk.

Top 10 Blue Chip Stocks To Watch Right Now: Gartner, Inc.(IT)

Advisors’ Opinion:

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Gartner (IT)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Lisa Levin] Companies Reporting Before The Bell
    Dean Foods Company (NYSE: DF) is projected to report quarterly earnings at $0.11 per share on revenue of $1.85 billion.
    Discovery, Inc. (NASDAQ: DISCA) is expected to report quarterly earnings at $0.44 per share on revenue of $1.99 billion.
    Jacobs Engineering Group Inc. (NYSE: JEC) is estimated to report quarterly earnings at $0.89 per share on revenue of $3.63 billion.
    Henry Schein, Inc. (NASDAQ: HSIC) is expected to report quarterly earnings at $0.92 per share on revenue of $3.17 billion.
    Gartner, Inc. (NYSE: IT) is projected to report quarterly earnings at $0.57 per share on revenue of $926.18 million.
    The AES Corporation (NYSE: AES) is estimated to report quarterly earnings at $0.24 per share on revenue of $2.98 billion.
    Expeditors International of Washington, Inc. (NASDAQ: EXPD) is projected to report quarterly earnings at $0.64 per share on revenue of $1.71 billion.
    US Foods Holding Corp. (NYSE: USFD) is expected to report quarterly earnings at $0.32 per share on revenue of $5.98 billion.
    DISH Network Corporation (NASDAQ: DISH) is expected to report quarterly earnings at $0.7 per share on revenue of $3.50 billion.
    Zebra Technologies Corporation (NASDAQ: ZBRA) is estimated to report quarterly earnings at $2.06 per share on revenue of $936.98 million.
    Camping World Holdings, Inc. (NYSE: CWH) is expected to report quarterly earnings at $0.42 per share on revenue of $1.06 billion.
    Perrigo Company plc (NYSE: PRGO) is projected to report quarterly earnings at $1.14 per share on revenue of $1.21 billion.
    Petróleo Brasileiro S.A. – Petrobras (NYSE: PBR) is estimated to report quarterly earnings at $0.28 per share on revenue of $23.80 billion.
    JD.com, Inc. (NYSE: JD) is projected to report quarterly earnings at $0.18 per share on revenue of $15.65 billion.
    Valeant Pharmaceuticals International, Inc. (NYSE: VRX) is projected to report quarterly earnings at $0.6 per share o
  • [By Demitrios Kalogeropoulos]

    Shares of research services specialist Gartner (NYSE:IT) outpaced the market by rising 11% last month compared to a 3% increase in the S&P 500, according to data provided by S&P Global Market Intelligence.

  • [By Steve Symington]

    Gartner Inc. (NYSE:IT) announced strong second-quarter 2018 results late Wednesday, highlighting broad-based growth across the business and the recent sale of several non-core segments.

Top 10 Blue Chip Stocks To Watch Right Now: Midstates Petroleum Company, Inc.(MPO)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Midstates Petroleum Company Inc (NYSE:MPO) shares reached a new 52-week low during trading on Wednesday . The stock traded as low as $11.50 and last traded at $11.58, with a volume of 2648 shares changing hands. The stock had previously closed at $12.02.

  • [By Stephan Byrd]

    Press coverage about Midstates Petroleum (NYSE:MPO) has trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Midstates Petroleum earned a daily sentiment score of 0.03 on Accern’s scale. Accern also assigned news headlines about the energy producer an impact score of 46.005644497441 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

  • [By Logan Wallace]

    News coverage about Midstates Petroleum (NYSE:MPO) has trended somewhat positive on Tuesday, Accern reports. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Midstates Petroleum earned a news sentiment score of 0.25 on Accern’s scale. Accern also gave news headlines about the energy producer an impact score of 46.8675209319962 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

  • [By Ethan Ryder]

    News stories about Midstates Petroleum (NYSE:MPO) have been trending somewhat positive on Tuesday, Accern reports. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Midstates Petroleum earned a news impact score of 0.25 on Accern’s scale. Accern also assigned headlines about the energy producer an impact score of 45.5617713297556 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Top 10 Blue Chip Stocks To Watch Right Now: Sempra Energy(SRE)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Sempra Energy (NYSE:SRE) had its price objective upped by analysts at Wells Fargo & Co from $126.00 to $128.00 in a report released on Monday. The firm currently has an “outperform” rating on the utilities provider’s stock. Wells Fargo & Co‘s target price suggests a potential upside of 12.16% from the stock’s current price.

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close was Sempra Energy (NYSE: SRE) which rose over 15% to $117.18. The stock’s 52-week range is $100.49 to $122.98. Volume was about 12 million compared to the daily average volume of 2 million.

  • [By Ethan Ryder]

    Sirius Real Estate Limited (LON:SRE) insider Andrew Coombs bought 400,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 14th. The shares were purchased at an average cost of GBX 65 ($0.87) per share, with a total value of £260,000 ($346,158.97).

  • [By Joseph Griffin]

    Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new position in Sempra Energy (NYSE:SRE) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 38,230 shares of the utilities provider’s stock, valued at approximately $4,439,000.

  • [By Shane Hupp]

    IFM Investors Pty Ltd raised its holdings in shares of Sempra Energy (NYSE:SRE) by 10.6% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,414 shares of the utilities provider’s stock after purchasing an additional 711 shares during the quarter. IFM Investors Pty Ltd’s holdings in Sempra Energy were worth $825,000 as of its most recent SEC filing.

  • [By Max Byerly]

    Fiduciary Financial Services of The Southwest Inc. TX lessened its position in shares of Sempra Energy (NYSE:SRE) by 6.0% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 22,499 shares of the utilities provider’s stock after selling 1,445 shares during the quarter. Fiduciary Financial Services of The Southwest Inc. TX’s holdings in Sempra Energy were worth $2,612,000 at the end of the most recent reporting period.

Top 10 Blue Chip Stocks To Watch Right Now: Exelixis, Inc.(EXEL)

Advisors’ Opinion:

  • [By Logan Wallace]

    Exelixis (NASDAQ:EXEL) was downgraded by investment analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued on Friday.

  • [By Dan Caplinger]

    Wall Street had another good session on Thursday, with further gains for major markets as benchmarks like the Russell 2000 index of small-cap stocks flirted with record highs. A favorable reading from the consumer price index showed only modest growth in prices, and the idea that inflation remains in check led market participants to believe that the Federal Reserve won’t have to speed up its efforts to return short-term interest rates to more normal levels. Yet even with the overall market picking up ground, some companies had bad news that weighed on their share prices. Booking Holdings (NASDAQ:BKNG), Exelixis (NASDAQ:EXEL), and L Brands (NYSE:LB) were among the worst performers on the day. Here’s why they did so poorly.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Exelixis (EXEL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Brian Orelli]

    Shares of Exelixis (NASDAQ:EXEL) have jumped 9.8% as of 11:47 a.m. EDT Thursday, having been up as much as 13% earlier, after the biotech released solid second-quarter earnings after the bell yesterday. The company continues to expand sales of its lead drug, Cabometyx, assuaging investors’ fears that competition might cut into the drug’s growth.

  • [By Sean Williams, Chuck Saletta, and Brian Feroldi]

    With this in mind, we asked three of our Motley Fool investors to name one healthcare stock they believe could be worth buying right now. Cancer drug developer Exelixis (NASDAQ:EXEL), generic-drug manufacturer Lannett (NYSE:LCI), and medical device megacap Medtronic (NYSE:MDT) all made the cut. 

Top 10 Blue Chip Stocks To Watch Right Now: Penn Virginia Resource Partners LP(PVR)

Advisors’ Opinion:

  • [By Stephan Byrd]

    PVR Partners, L.P. (PVR) is engaged in the gathering and processing of natural gas and the management of coal and natural resource properties in the United States. The Company operates in three business segments: Eastern Midstream, Midcontinent Midstream and Coal and Natural Resource Management. In March 2014, Regency Energy Partners LP announced that it has acquired acquires all of PVR Partners, L.P’s outstanding units.

Top 10 Blue Chip Stocks To Watch Right Now: OCI Partners LP(OCIP)

Advisors’ Opinion:

  • [By Joseph Griffin]

    OCI Partners (NYSE:OCIP) shares hit a new 52-week high and low on Monday . The company traded as low as $10.45 and last traded at $10.45, with a volume of 1357 shares changing hands. The stock had previously closed at $10.40.

  • [By Logan Wallace]

    ASAHI KASEI Cor/ADR (NYSE: OCIP) and OCI Partners (NYSE:OCIP) are both basic materials companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability.

  • [By Shane Hupp]

    Shares of OCI Partners (NYSE:OCIP) hit a new 52-week high and low during mid-day trading on Wednesday . The stock traded as low as $10.00 and last traded at $9.85, with a volume of 0 shares traded.

Top 10 Blue Chip Stocks To Watch Right Now: Greene County Bancorp, Inc.(GCBC)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Greene County Bancorp (NASDAQ: GCBC) and Heritage Financial (NASDAQ:HFWA) are both small-cap finance companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, dividends, valuation, earnings, profitability and analyst recommendations.

  • [By Joseph Griffin]

    BidaskClub upgraded shares of Greene County Bancorp (NASDAQ:GCBC) from a strong sell rating to a sell rating in a research note issued to investors on Tuesday.

Top 10 Blue Chip Stocks To Watch Right Now: Warren Resources Inc.(WRES)

Advisors’ Opinion:

  • [By Shane Hupp]

    Northland Securities restated their corporate rating on shares of W Resources (LON:WRES) in a research note issued to investors on Wednesday.

    Shares of LON WRES opened at GBX 0.43 ($0.01) on Wednesday. W Resources has a 52 week low of GBX 0.25 ($0.00) and a 52 week high of GBX 0.72 ($0.01).

Top 10 Blue Chip Stocks To Watch Right Now: BankUnited, Inc.(BKU)

Advisors’ Opinion:

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on BankUnited (BKU)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Teacher Retirement System of Texas trimmed its holdings in BankUnited (NYSE:BKU) by 35.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,661 shares of the financial services provider’s stock after selling 13,097 shares during the period. Teacher Retirement System of Texas’ holdings in BankUnited were worth $946,000 as of its most recent filing with the Securities & Exchange Commission.

  • [By Stephan Byrd]

    BankUnited (NYSE:BKU) reached a new 52-week high and low on Thursday . The stock traded as low as $44.17 and last traded at $43.79, with a volume of 44855 shares traded. The stock had previously closed at $43.75.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on BankUnited (BKU)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:

    Get BankUnited alerts:

    BankUnited (BKU) Expected to Post Quarterly Sales of $277.17 Million (americanbankingnews.com) BankUnited (BKU) Insider Sells $40,630.00 in Stock (americanbankingnews.com) BankUnited (BKU) Expected to Announce Earnings of $0.79 Per Share (americanbankingnews.com) Head to Head Contrast: BankUnited (BKU) and Capitol Federal Financial (CFFN) (americanbankingnews.com)

    NYSE BKU opened at $40.62 on Wednesday. BankUnited has a 12-month low of $30.37 and a 12-month high of $43.84. The company has a debt-to-equity ratio of 1.58, a quick ratio of 0.96 and a current ratio of 0.96. The company has a market capitalization of $4.30 billion, a PE ratio of 15.33, a price-to-earnings-growth ratio of 1.39 and a beta of 1.04.

Top 5 Clean Energy Stocks To Own For 2019

If you’re looking to invest in renewable power stocks, you can always pick out pure plays that take advantage of the huge demand for clean energy — and with utility customers inking long-term power contracts as they switch from dirty carbon-based fuels, that might be a winning strategy. However, what if the growth story behind renewables doesn’t live up to today’s hype?

That uncertainty is why a diversified company like NextEra Energy, Inc. (NYSE:NEE), with utility and renewable power operations, might make more sense for conservative investors.

Focusing on renewables

There’s no question that a company like Brookfield Renewable Partners L.P. (NYSE:BEP) is a great direct play on renewable power. Roughly 80% of the company’s power is hydroelectric, with the rest made up largely of wind and solar. Moreover, it has exposure to Brazil (20% of generation) and Columbia (15%), in addition to the United States (60%). Much of the company’s growth has come from acquisitions, and long-term contracts back up the bulk of its revenues. It’s a perfectly fine renewable power investment.

Top 5 Clean Energy Stocks To Own For 2019: Aquinox Pharmaceuticals, Inc.(AQXP)

Advisors’ Opinion:

  • [By Paul Ausick]

    Aquinox Pharmaceuticals Inc. (NASDAQ: AQXP) dropped about nearly 85% Wednesday to post a new 52-week low of $2.25. Shares closed at $15.31 on Tuesday and the stock’s 52-week high is $16.90. Volume totaled 13.5 million shares compared to a daily average of less than 200,000. The company’s bladder pain drug failed a trial and the company is stopping development.

  • [By Logan Wallace]

    Aquinox Pharmaceuticals (NASDAQ:AQXP) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a report released on Monday.

  • [By Ethan Ryder]

    Cantor Fitzgerald reiterated their neutral rating on shares of Aquinox Pharmaceuticals (NASDAQ:AQXP) in a research report report published on Wednesday, MarketBeat.com reports.

  • [By Max Byerly]

    Shares of Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) have received an average recommendation of “Buy” from the seven research firms that are covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year target price among brokers that have covered the stock in the last year is $25.25.

Top 5 Clean Energy Stocks To Own For 2019: Exelixis, Inc.(EXEL)

Advisors’ Opinion:

  • [By Max Byerly]

    BidaskClub upgraded shares of Exelixis (NASDAQ:EXEL) from a strong sell rating to a sell rating in a report released on Friday.

    EXEL has been the subject of a number of other research reports. Cann restated a buy rating and set a $40.00 price objective on shares of Exelixis in a research note on Wednesday, May 30th. ValuEngine lowered Exelixis from a sell rating to a strong sell rating in a research note on Friday, May 11th. William Blair reaffirmed a buy rating on shares of Exelixis in a report on Wednesday, April 11th. Oppenheimer raised Exelixis from a market perform rating to an outperform rating and set a $40.00 target price on the stock in a report on Tuesday, February 27th. Finally, Stifel Nicolaus reduced their target price on Exelixis from $30.00 to $29.00 and set a hold rating on the stock in a report on Thursday, May 3rd. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and nine have issued a buy rating to the company’s stock. The company has a consensus rating of Hold and an average price target of $32.80.

  • [By Ethan Ryder]

    Exelixis (NASDAQ:EXEL) EVP Jeffrey Hessekiel sold 20,000 shares of the company’s stock in a transaction dated Friday, May 4th. The stock was sold at an average price of $22.36, for a total transaction of $447,200.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

  • [By Shane Hupp]

    Old Mutual Global Investors UK Ltd. raised its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 26.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,562,369 shares of the biotechnology company’s stock after purchasing an additional 747,398 shares during the quarter. Old Mutual Global Investors UK Ltd. owned 1.20% of Exelixis worth $78,906,000 as of its most recent SEC filing.

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    MDC Partners Inc. (NASDAQ: MDCA) fell 23.4 percent to $5.25 in pre-market trading after a first-quarter earnings miss.
    Hudson Technologies Inc. (NASDAQ: HDSN) shares fell 15.1 percent to $3.48 in pre-market trading after the company reported downbeat Q1 earnings.
    Nuance Communications, Inc. (NASDAQ: NUAN) fell 14 percent to $13.15 in pre-market trading after the company posted downbeat Q2 earnings and lowered FY18 organic growth guidance.
    Myomo, Inc. (NYSE: MYO) fell 13.2 percent to $3.10 in pre-market trading after reporting downbeat quarterly results.
    Rowan Companies plc (NYSE: RDC) shares fell 10.7 percent to $14.13 in pre-market trading after climbing 8.50 percent on Wednesday.
    BT Group plc (NYSE: BT) fell 9 percent to $14.80 in pre-market trading after the company reported Q4 results and announced plans to cut 13,000 jobs over the next three years.
    Exelixis, Inc. (NASDAQ: EXEL) fell 8.3 percent to $19.90 in pre-market trading after the company disclosed that IMblaze370 Phase 3 pivotal trial of atezolizumab and cobimetinib in patients with heavily pretreated locally advanced or metastatic colorectal cancer did not meet primary endpoint.
    Infinera Corporation (NASDAQ: INFN) fell 8.2 percent to $10.80 in pre-market trading after reporting Q1 results.
    Synaptics, Incorporated (NASDAQ: SYNA) shares fell 7.4 percent to $43.00 in pre-market trading. Synaptics reported better-than-expected earnings for its third quarter, while sales missed estimates.
    Randgold Resources Limited (NASDAQ: GOLD) shares fell 7.4 percent to $76.23 in pre-market trading after reporting Q1 earnings.
    Integra LifeSciences Holdings Corporation (NASDAQ: IART) shares fell 7 percent to $59.36 in pre-market trading. Integra LifeSciences priced its 5.25 million share public offering of common stock at $58.50 per share.
    Array BioPharma Inc. (NASDAQ: ARRY) shares fell 6.9 percent to $12.75 in pre-m

  • [By Ethan Ryder]

    Exelixis (NASDAQ:EXEL) – Investment analysts at William Blair raised their FY2018 earnings per share (EPS) estimates for shares of Exelixis in a research report issued to clients and investors on Thursday, May 3rd. William Blair analyst A. Hsieh now anticipates that the biotechnology company will post earnings per share of $0.90 for the year, up from their previous estimate of $0.66. William Blair currently has a “Buy” rating on the stock. William Blair also issued estimates for Exelixis’ Q1 2019 earnings at $0.23 EPS, Q2 2019 earnings at $0.25 EPS, Q3 2019 earnings at $0.27 EPS and Q4 2019 earnings at $0.29 EPS.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Exelixis (EXEL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Clean Energy Stocks To Own For 2019: Communications Systems Inc.(JCS)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Cara Therapeutics, Inc. (NASDAQ: CARA) shares surged 42.76 percent to close at $16.56 on Wednesday in reaction to a new licensing agreement with Europe-based Vifor Pharma. As part of the agreement, the biopharmaceutical company that alleviates pain licensed worldwide rights (except U.S., Japan, and South Korea) to Vifor Pharma to commercialize its KORSUVA therapy to Vifor $70 million.
    Yangtze River Port and Logistics Limited (NASDAQ: YRIV) gained 31.28 percent to close at $7.05 on Wednesday.
    Tiffany & Co. (NYSE: TIF) climbed 23.29 percent to close at $126.05 after the company reported upbeat results for its first quarter and raised its FY2018 earnings guidance.
    EVO Payments, Inc. (NASDAQ: EVOP) gained 18.88 percent to close at $19.02. EVO Payments priced its IPO at $16 per share.
    Carver Bancorp, Inc. (NASDAQ: CARV) rose 16.1 percent to close at $6.85.
    USA Technologies, Inc. (NASDAQ: USAT) gained 15.68 percent to close at $13.65 after announcing pricing of public offering.
    eXp World Holdings, Inc. (NASDAQ: EXPI) shares jumped 15.01 percent to close at $17.70.
    Geron Corporation (NASDAQ: GERN) gained 14.99 percent to close at $4.68.
    Evolus, Inc. (NASDAQ: EOLS) rose 14.62 percent to close at $19.36.
    Ralph Lauren Corporation (NYSE: RL) shares rose 14.34 percent to close at $133.33 after the company reported stronger-than-expected results for its fourth quarter.
    Turtle Beach Corporation (NASDAQ: HEAR) jumped 13.26 percent to close at $17.34 on Wednesday. Turtle Beach S-3 showed registration for 1.857 million share common stock offering via selling holders.
    Communications Systems, Inc. (NASDAQ: JCS) rose 13.18 percent to close at $3.95. Communications Systems reported establishment of special committee to explore strategic alternatives.
    Immutep Limited (NASDAQ: IMMP) shares climbed 12.95 percent to close at $2.53.
    xG Technology, Inc. (NASDAQ: XGTI) rose 12.64 percent to close at $0.8561 after the company&rsq

Top 5 Clean Energy Stocks To Own For 2019: Frontline Ltd.(FRO)

Advisors’ Opinion:

  • [By Logan Wallace]

    Pyxis Tankers (NASDAQ: PXS) and Frontline (NYSE:FRO) are both small-cap transportation companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability and analyst recommendations.

  • [By Asit Sharma]

    Last year, net income dropped from $146.4 million to $101.2 million, creating the sharp trend line seen above. The 2017 earnings dip can be traced to numerous factors, including higher interest expense, a reduction in tanker income, fewer ships in the fleet on charter to former parent Frontline Shipping (NYSE:FRO), and the bankruptcy filing of Seadrill Ltd. (NYSE:SDRL). Seadrill’s reorganization has impacted Ship Finance’s offshore revenue, as it has three out of four offshore drilling rigs on charter to affiliates of Seadrill.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Frontline (FRO)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Matthew DiLallo]

    Shares of Frontline Ltd.(NYSE:FRO) surged more than 13% by 10:00 a.m. EDT on Thursday after the oil tanker company posted better-than-expected first-quarter results.

  • [By Lisa Levin] Gainers
    Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) jumped 124.8 percent to $243.725 in reaction to an encouraging Phase 2 clinical trial update. The clinical-stage biopharmaceutical company said its liver-directed, thyroid hormone receptor called MGL-3196 showed a statistical significance in the primary endpoint of lowering liver fat at 12 weeks and also 36 weeks.
    Viking Therapeutics, Inc. (NASDAQ: VKTX) gained 63.4 percent to $8.12 after falling 4.42 percent on Wednesday.
    Takung Art Co., Ltd. (NYSE: TKAT) rose 43.3 percent to $2.9094
    vTv Therapeutics Inc. (NASDAQ: VTVT) shares climbed 29.7 percent to $2.16 after the company reported a licensing deal with Newsoara Biopharma to rights for vTv's PDE4 Inhibitor in China and other Pacific Rim territories.
    Akers Biosciences, Inc. (NASDAQ: AKER) gained 26.2 percent to $0.4109. The developer of rapid health information technologies said Wednesday afternoon it was granted a 180-day extension from the Nasdaq Stock Market to meet the requirement of a minimum $1.00 per share closing bid price for 10 straight days.
    Genprex, Inc. (NASDAQ: GNPX) rose 22.2 percent to $11.6254. Genprex reported engagement of WIRB-Copernicus Group to provide clinical trial services to support Oncoprex clinical trial program.
    J.Jill, Inc. (NYSE: JILL) gained 21 percent to $7.506 after the company posted upbeat quarterly earnings.
    Urban One, Inc. (NASDAQ: UONE) gained 19.7 percent to $3.95 after rising 78.38 percent on Wednesday.
    TapImmune, Inc. (NASDAQ: TPIV) shares gained 18.5 percent to $6.03 after climbing 24.15 percent on Wednesday.
    Kirkland's, Inc. (NASDAQ: KIRK) rose 17.3 percent to $12.95 after reporting upbeat Q1 results.
    CymaBay Therapeutics, Inc. (NASDAQ: CBAY) shares gained 15.1 percent to $13.210.
    The Brink's Company (NYSE: BCO) climbed 14.2 percent to $77.875 as the company announced plans to acquire Dunbar Armored for $520 million in cash.
    Keysight Technologies, Inc. (NYSE: KEY
  • [By ]

    What Happened
    Shares of Frontline Ltd. (NYSE:FRO) surged more than 13% by 10:00 a.m. EDT on Thursday after the oil tanker company posted better-than-expected first-quarter results.

Top 5 Clean Energy Stocks To Own For 2019: LivePerson Inc.(LPSN)

Advisors’ Opinion:

  • [By Joseph Griffin]

    LivePerson (NASDAQ:LPSN) released its quarterly earnings results on Thursday. The technology company reported $0.01 EPS for the quarter, Bloomberg Earnings reports. LivePerson had a negative return on equity of 2.93% and a negative net margin of 6.95%. The company had revenue of $58.24 million for the quarter, compared to analysts’ expectations of $57.22 million. During the same period in the prior year, the firm earned $0.01 earnings per share. The firm’s revenue was up 14.4% compared to the same quarter last year. LivePerson updated its Q2 guidance to $0.00-0.01 EPS and its FY18 guidance to $0.11-0.15 EPS.

  • [By Logan Wallace]

    LivePerson, Inc. (NASDAQ:LPSN) SVP Daryl Carlough sold 425 shares of the company’s stock in a transaction dated Wednesday, June 20th. The shares were sold at an average price of $23.80, for a total value of $10,115.00. Following the completion of the sale, the senior vice president now directly owns 14,647 shares of the company’s stock, valued at $348,598.60. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

  • [By Logan Wallace]

    Mobileye (OTCMKTS: MBBYF) and LivePerson (NASDAQ:LPSN) are both computer and technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

  • [By Shane Hupp]

    LivePerson (NASDAQ:LPSN) updated its FY18 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $0.11-0.15 for the period, compared to the Thomson Reuters consensus estimate of $0.09. The company issued revenue guidance of $239-243 million, compared to the consensus revenue estimate of $239.45 million.LivePerson also updated its Q2 guidance to $0.00-0.01 EPS.

  • [By Rick Munarriz]

    Double-digit growth is back at LivePerson (NASDAQ:LPSN). The provider of high-tech customer support reported fresh financials after Thursday’s market close, delivering its best period of year-over-year revenue growth in nearly three years.

Top 10 Performing Stocks To Watch For 2018

Molson Coors Brewing Company (NYSE:TAP) has been underperforming peers since October 2016, or since the remaining purchase of Miller Coors was announced. In my point of view, it is only a matter of time until the market rewards managements effort to drive shareholder value, and 2018 could be that year. Shares declined by more than 30% since its peak and now trade at a reasonable valuation of 16 price-to-forward looking earnings, and at a significant discount compared to Heinekens (OTCQX:HEINY) price-to-forward looking earnings of 21 and Anheuser-Busch InBev’s (NYSE:BUD) 21.

Management is focusing on debt reduction and managing the product mix better to increase profitability. Earnings from the recent quarter prove that management is capable of increasing efficiency, and because the company generates significant free cash flow, the debt repayments towards a more sustainable level should not be a problem. Hence, I think Molson Coors will catch up with peers valuation.

From a technical perspective, the best entry would be in the low $70s, 10% lower compared to the current price, but the likelihood that the price reaches that level is not that high. Hence, the good strategy could be to use the recent sell-off and start allocating shares, and if the price reaches $70, then to increase the position and benefit from historical bullish price action around that level.

Top 10 Performing Stocks To Watch For 2018: Northern Oil and Gas, Inc.(NOG)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Northern Oil and Gas Inc. (NYSEAMERICAN:NOG) has received a consensus recommendation of “Hold” from the eight research firms that are presently covering the firm, MarketBeat.com reports. Seven investment analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 12 month price target among brokers that have covered the stock in the last year is $2.20.

  • [By Matthew DiLallo]

    Shares of Northern Oil & Gas, Inc. (NYSEMKT:NOG) are flying high, up 12% as of 10:30 a.m. EDT, after the company reported better-than-expected first-quarter results.

Top 10 Performing Stocks To Watch For 2018: Optical Cable Corporation(OCC)

Advisors’ Opinion:

  • [By Logan Wallace]

    Octoin Coin (CURRENCY:OCC) traded 7% higher against the US dollar during the 24 hour period ending at 19:00 PM Eastern on May 12th. One Octoin Coin coin can now be bought for approximately $2.51 or 0.00029499 BTC on popular exchanges including Exrates and YoBit. Octoin Coin has a market cap of $926,548.00 and approximately $1.02 million worth of Octoin Coin was traded on exchanges in the last day. In the last week, Octoin Coin has traded 23.4% lower against the US dollar.

Top 10 Performing Stocks To Watch For 2018: Taylor Morrison Home Corporation(TMHC)

Advisors’ Opinion:

  • [By ]

    Higher rates can hurt stocks of companies like homebuilders, which rely on affordable mortgage rates for their customers. “Nobody trusts the homebuilders past the day they report because the litany is always: ‘This is the last good quarter when it comes to Lennar (LEN) , Toll Brothers (TOL) , D.R. Horton (DHI) , Taylor Morrison (TMHC) and PulteGroup (PHM) .'”

  • [By ]

    In his second “Executive Decision” segment, Cramer sat down with Sheryl Palmer, chairman, president and CEO of Taylor Morrison Homes (TMHC) , for a read on the state of the housing market.

Top 10 Performing Stocks To Watch For 2018: Exelixis, Inc.(EXEL)

Advisors’ Opinion:

  • [By Brian Orelli]

    Shares of Exelixis (NASDAQ:EXEL) are down 12% at 2:02 p.m. EDT after announcing the IMblaze370 phase 3 trial testing its Cotellic with Roche’s Tecentriq failed to improve overall survival compared to Bayer’s Stivarga in patients with locally advanced or metastatic colorectal cancer.

  • [By Todd Campbell]

    Technology stocks are staples in growth portfolios because of their eye-popping revenue growth, but technology isn’t the only sector of the stock market that boasts fast-growing companies. For example, many healthcare stocks are growing at rates that Silicon Valley would envy. In fact, Foundation Medicine (NASDAQ:FMI), Exelixis Corp (NASDAQ:EXEL), and Teladoc (NYSE:TDOC) all reported year-over-year sales growth north of 100% in first-quarter 2018.

  • [By Joseph Griffin]

    Exelixis (NASDAQ:EXEL) – Equities researchers at Oppenheimer raised their Q2 2018 earnings per share (EPS) estimates for Exelixis in a report issued on Wednesday, May 2nd. Oppenheimer analyst L. Cann now forecasts that the biotechnology company will post earnings of $0.11 per share for the quarter, up from their prior forecast of $0.09. Oppenheimer currently has a “Outperform” rating and a $40.00 target price on the stock. Oppenheimer also issued estimates for Exelixis’ Q3 2018 earnings at $0.13 EPS, Q4 2018 earnings at $0.14 EPS and FY2018 earnings at $0.74 EPS.

  • [By Stephan Byrd]

    Wedbush Securities Inc. purchased a new position in shares of Exelixis (NASDAQ:EXEL) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 14,215 shares of the biotechnology company’s stock, valued at approximately $315,000.

Top 10 Performing Stocks To Watch For 2018: InfraREIT, Inc.(HIFR)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on InfraREIT (HIFR)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Shane Hupp]

    Reaves W H & Co. Inc. trimmed its holdings in InfraREIT (NYSE:HIFR) by 18.4% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,342,026 shares of the real estate investment trust’s stock after selling 303,392 shares during the quarter. Reaves W H & Co. Inc. owned approximately 3.05% of InfraREIT worth $26,076,000 as of its most recent SEC filing.

Top 10 Performing Stocks To Watch For 2018: Potash Corporation of Saskatchewan Inc.(POT)

Advisors’ Opinion:

  • [By Joseph Griffin]

    PotCoin (CURRENCY:POT) traded 0.6% higher against the US dollar during the 24 hour period ending at 23:00 PM E.T. on May 12th. PotCoin has a total market capitalization of $23.95 million and approximately $62,522.00 worth of PotCoin was traded on exchanges in the last 24 hours. During the last seven days, PotCoin has traded 17.8% lower against the US dollar. One PotCoin coin can now be purchased for approximately $0.11 or 0.00001293 BTC on popular cryptocurrency exchanges including Cryptopia, CoinExchange, Trade By Trade and Tux Exchange.

Top 10 Performing Stocks To Watch For 2018: United States Steel Corporation(X)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows shares of Steel Dynamics outperforming peers such as large cap Nucor Corporation (NYSE: NUE) and mid cap United States Steel Corporation (NYSE: X) along with Market Vectors Steel ETF (NYSEARCA: SLX):

  • [By Joseph Griffin]

    Commerzbank Aktiengesellschaft FI trimmed its holdings in shares of U.S. Steel (NYSE:X) by 3.7% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 121,345 shares of the basic materials company’s stock after selling 4,606 shares during the period. Commerzbank Aktiengesellschaft FI’s holdings in U.S. Steel were worth $4,270,000 as of its most recent SEC filing.

  • [By Jon C. Ogg]

    United States Steel Corp. (NYSE: X) is not feeling any love from investors after earnings. Maybe tariffs and fears of a trade war really don’t help when it hurts a company’s customers and end-users. The reality is that there are concerns over tariffs, but there is also concern about operational issues in North America affecting the results and making for a bumpy outlook in 2018.

  • [By Alexander Bird]

    American steel maker AK Steel Holding Corp. (NYSE: AKS) jumped 9.5%, while U.S. Steel Corp. (NYSE: X) rose 5.7%.

    Aluminum producer Century Aluminum Co. (Nasdaq: CENX) added 3.3%to its share price, and Alcoa Corp. (NYSE: AA) edged up 0.2%, both closing out the day with gains.

  • [By ]

    Tariffs or no tariffs, steel and aluminum stocks have enjoyed one heck of a comeback move over the past six months. US Steel Group Inc. (NYSE:X) is up almost 75% over the past six months:

  • [By ]

    You can see why Century Aluminum (Nasdaq: CENX) commended the President for “acting swiftly and boldly to save the American aluminum industry.” The company intends to ramp up operations at its smelter in Hawesville, Kentucky, putting 300 people back to work. In Illinois, US Steel (NYSE: X) is restarting a blast furnace that will employ at least 500 new workers.

Top 10 Performing Stocks To Watch For 2018: Watts Water Technologies, Inc.(WTS)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Watts Water Technologies (NYSE: WTS) and ARC Group WorldWide (NASDAQ:ARCW) are both computer and technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, dividends and analyst recommendations.

  • [By Stephan Byrd]

    A number of institutional investors and hedge funds have recently made changes to their positions in WTS. SeaCrest Wealth Management LLC acquired a new position in Watts Water Technologies during the fourth quarter worth about $112,000. Xact Kapitalforvaltning AB acquired a new position in shares of Watts Water Technologies in the fourth quarter valued at approximately $224,000. Sawgrass Asset Management LLC acquired a new position in shares of Watts Water Technologies in the fourth quarter valued at approximately $270,000. Koch Industries Inc. raised its position in shares of Watts Water Technologies by 22.0% in the fourth quarter. Koch Industries Inc. now owns 3,821 shares of the technology company’s stock valued at $290,000 after buying an additional 690 shares during the last quarter. Finally, Quadrature Capital Ltd acquired a new position in shares of Watts Water Technologies in the fourth quarter valued at approximately $330,000. Institutional investors own 77.22% of the company’s stock.

    ILLEGAL ACTIVITY NOTICE: “Watts Water Technologies (WTS) Expected to Post Quarterly Sales of $362.52 Million” was originally posted by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3380368/watts-water-technologies-wts-expected-to-post-quarterly-sales-of-362-52-million.html.

    Watts Water Technologies Company Profile

Top 10 Performing Stocks To Watch For 2018: Compugen Ltd.(CGEN)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Compugen (NASDAQ:CGEN) – Equities researchers at Jefferies Group increased their Q2 2018 earnings estimates for shares of Compugen in a research note issued on Wednesday, May 9th. Jefferies Group analyst P. Welford now anticipates that the biotechnology company will earn ($0.20) per share for the quarter, up from their prior forecast of ($0.21). Jefferies Group also issued estimates for Compugen’s Q4 2018 earnings at ($0.05) EPS, FY2018 earnings at ($0.46) EPS, FY2019 earnings at ($1.00) EPS, FY2020 earnings at ($1.19) EPS, FY2021 earnings at ($1.37) EPS and FY2022 earnings at ($1.58) EPS.

Top 10 Performing Stocks To Watch For 2018: Telecom Italia S.P.A.(TI)

Advisors’ Opinion:

  • [By Max Byerly]

    TIM (NYSE:TI) was downgraded by equities researchers at Berenberg Bank from a “hold” rating to a “sell” rating in a report released on Friday, The Fly reports.

NewLink Genetics: Explicating The Changing Fundamentals Of A Potential Comeback

We all are learning, modifying, or destroying ideas all the time. Rapid destruction of your ideas when the time is right is one of the most valuable qualities you can acquire. You must force yourself to consider arguments on the other side. – Charlie Munger

NewLink Genetics (NASDAQ:NLNK) is a highly interesting bioscience, undergoing significant fundamental shifts for making a strong comeback. The company is powered by a stellar anti-cancer molecule (indoximod) that, in and of itself, is best employed in a combination regimen: we noted in the prior research on Exelixis (NASDAQ:EXEL) that combination medicines tend to work best for cancers due to the rogue cells adeptness at evading immune response.

As alluded, NewLink recently decided to terminate the development of two segments (advanced melanoma and pancreatic cancers). Consequently, this action is most likely to preserve the cash needed for other pipeline developments. Substantial value can be added to their pipeline (depending on which cancers the company pursues). Ultimately, this can translate into more fortunes for shareholders as well as newfound hopes for patients worldwide. In this research, well elucidate the underlying fundamentals of NewLink and the pertinent catalysts that can catapult the shares to a new valuation.

Figure 1: NewLink stock chart. (Source: StockCharts)

Fundamental Analysis

Based in Ames IA, NewLink Genetics is focusing on the therapeutic innovation and commercialization to service highly difficult-to-manage cancers. In harnessing the power of a novel agent (indoximod), the company is currently brewing an interesting pipeline (as depicted in figure 2). Nevertheless, the firm is making adjustments to its clinical development that well later elucidate. First, we wish to feature the underlying science powering this grower.

Figure 2: Therapeutic pipeline. (Source: NewLink Genetics)

As follows, the indoleamine 2,3-dioxygenase (IDO) pathway regulates the immune (i.e. body natural defense) responses by inhibiting T-cell function, thereby enabling tumors to escape the immune detection. Interestingly, the company is investigating two differentiated candidates that target the IDO pathways: (1) indoximod, the most advanced molecules with multiple Phase 2 trials across various cancer indications, and (2) NLG802, a prodrug of indoximod that entered the clinic in 2017.

The aforementioned (IDO) is one of several key regulators involved in the phenomenon coined immune escape, in which the tumors evolved to become non-susceptible to immune defenses. This is accomplished by the increase in IDO expression via the antigen-presenting cells (APC) that, in and of itself, leads to the depletion of a key amino acid (tryptophan). Without adequate tryptophan, the antigen-specific T cell and regulatory T cell – the generals of the immune system – die off. And thus, cancers are allowed to propagate uncontrollably.

Figure 3: Indoximod mechanism of action (Source: NewLink Genetics)

For Q1 2018 (ended on March 31), NewLink reported $18.3M ($0.49 per share) net losses compared to the $20.9M ($0.72 per share) decline for the same period a year prior. In addition, the company ended the quarter with $143.9M net cash versus $158.7M for the similar period. Given that the company had to step down the development of pancreatic cancer and advanced melanoma, we expect the spending to be lower going forward.

Based on the $73M annual burn rate, there should be adequate cash to fund operations for the next two years (prior to additional financing). Investors should be cognizant that it is the norm for a young bioscience to incur significant losses for many years prior to banking a net profit (due to the lengthy and low success rate of the innovation process). Be that as it may, it only takes one blockbuster to make your investment worthwhile.

Interestingly, NewLink stated that the company is going to make key changes to its pipeline advancement in the latest quarterly report. After a thorough assessment, the company abandoned the commencement of the Phase 3 trial (re indoximod in combo with a PD-1 inhibitor) for patients afflicted by advanced melanoma.

Additionally, the firm mutually agreed with its partner AstraZeneca (NYSE:AZN) to not proceed with the Phase 2 study for pancreatic cancer. Contrary to the market interpretation, this is actually quite prudent. Both advanced melanoma and pancreatic cancers are extremely difficult to treat. Therefore, the chances of delivering positive clinical outcomes for such diseases are minuscule.

Evidently, its more strategic for NewLink to focus on other indications with more chances of success. And, the company will update investors with the definitive decision during the Q2 reporting. In steering away from the nearly insurmountable battles, at least a billion dollars of expenses would be saved. This strategy exemplifies the insight of Warren Buffett: I don’t look to jump over seven-foot bars; I look around for one-foot bars that I can step over.

Final Remarks

It is without doubt that NewLink is holding a stellar and unique medicine (efficacious and safe against various cancers). Based on its mechanism of action, indoximod is best employed in the combination regimen. The recent corporate decision to step down advanced melanoma and pancreatic franchises is the key catalyst for a successful turnaround. Else, the future clinical outcomes would likely turn out to be disappointing. At this point in the companys growth cycle, we only recommend investors to initiate a small pilot position.

Well have a better idea of the prospects during the Q2 reporting when the firm gives further guidance on the pipeline advancement. In terms of risks, the main concerns for NewLink is if indoximod can deliver positive clinical outcomes. As alluded, if the company focuses on the easier to treat cancers (rather than advanced or resistant cases), the risks would be substantially deleveraged. A negative binary event can cause the shares to tumble substantially and vice versa. Moreover, even if the aforesaid medicine will be approved, it might not generate substantial sales due to market competition and other unforeseen variables.

Authors Notes: Were honored that you took the time to read our market intelligence. Founded by Dr. Hung Tran, MD, MS, CNPR, (in collaborations with Analyst Vu, and other PhDs), Integrated BioSci Investing (IBI) is delivering stellar returns. To name a few, Nektar, Spectrum, Atara, and Kite procured over 355%, 132%, 237%, and 83% profits, respectively. Our secret sauce is extreme due diligence with expert data analysis. The service features a once-weekly exclusive Alpha-Intelligence article, daily analysis/consulting, and model portfolios. Of note, there is an IBI version of this article that is a higher-level intelligence with extensive details, in which we published in advanced and exclusively for our subscribers. And, we invite you to subscribe to our marketplace now to lock in the current price and save money for the future.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: I like to inform our readers of Seeking Alpha’s recent policy change, in which the company implemented the paywall (not only to my articles but to all articles that are published over 10-day). This is in place, as the company is, after all, a business. And, the revenues from ads are not adequate to support the high-quality research that the company is providing. If you are a REAL TIME FOLLOWER, you will be notified immediately of our new research for you to continue to benefit from our due diligence. You can also gain access to all of my old articles and much more by taking the 2-week FREE trial of my marketplace, Integrated BioSci Investing.

Exelixis: Time To Excel

Exelixis (NASDAQ:EXEL) has seen a very difficult 2018 so far, after the company has seen a very impressive momentum run in 2016 and 2017 following strong clinical results for CABOMETYX, approval of this drug and a good start to sales in the first quarters following launch.

Earlier this year, I looked at the prospects for the business. At the time, shares were trading at around $30, as the business was awarded a $10 billion valuation. I applauded the multiple options and revenues for growth, as well as the impressive performance of CABOMETYX, prompting me to take a small speculative position (about a fifth of my targeted long position).

Investors Need Patience

Exelixis has been founded back in the 1990s, and despite partnerships with some of the industry’s top-notch names, including GlaxoSmithKline (NYSE:GSK) and Bristol-Myers Squibb (NYSE:BMY), the company never really got anywhere in the years to follow.

It was finally granted approval for cabozantinib/COMETRIQ, but ironically, this drug nearly bankrupted the company. Sales came in at $42 million in 2016, fell to $25 million and subsequently ran at a lower annual pace as investments into this drug (including selling & marketing expenses) nearly bankrupted the company.

Just in time approval came in for cabozantinib/CABOMETYX to treat patients with advanced renal cell carcinoma, a form of kidney cancer. The drug debuted in the second quarter of 2016 and sales came in nearly $18 million for the (partial) quarter, to grow to $31 million in Q3 and nearly $45 million in the final quarter of the year. The company saw continued growth in 2017 as sales rose to $62 million in Q1, $81 million in the second quarter and more than $90 million in the third quarter. Disappointing was the fact that fourth-quarter sales were flat compared to Q3, as the pick-up in sales between Q2 and Q3 was a bit lower already as well.

I noted in my previous article that the first quarter of 2018 would receive additional interest from me for two reasons. For starters was the disappointing growth in Q4 (on a sequential basis). The other reason was the decision by the FDA to approve CABOMETYX for all patients with advanced renal carcinoma (“RCC”) instead of the initial approval, which was for a more selected group of patients.

The Much-Awaited Q1

Early May, Exelixis finally reported the much-awaited quarterly results, as sales of CABOMETYX came in at $128.9 million in the first quarter, a near-$39 million pick-up from the fourth-quarter results. Revenues of COMETRIQ were flattish at $5.3 million, for a $21 million run rate. The pick-up in CABOMETYX did not come as a complete surprise after management guided for a 20% sequential increase in sales data in January, when it held the conference call for the Q4 results.

The company reported a huge $116 million operating profit number for the quarter, but the results were positively influenced by the $78 million in collaboration revenues, which includes many incidentals/milestone payments following FDA approval to have wider administration for CABOMETYX. Stripping out all these collaboration revenues, operating earnings still came in at $38 million. After applying a 20% tax rate, that will work out to $0.10 per share in earnings.

Despite the reasonable pick-up in sales, the market has not been too enthusiastic, as shares have fallen from $30 to $20 by now. With 313 million shares outstanding, the business is valued at $6.2 billion, even as cash balances have now surpassed half a billion, for a $5.7 billion operating asset valuation. With product revenues running at an annualised rate of $540 million per annum, sales multiples are compressing quite rapidly to about 10 times, not even taking into account the collaboration revenues just yet.

The potential is huge, of course. Following the approval to promote CABOMETYX to all lines of patients diagnosed with liver cancer, the company is working hard to test the drug on patients with other tumor types, although investors need to have patience to see these efforts come to fruition.

Appeal Is Increasing

To be fair, I do not think there is anything wrong with the first-quarter results, as further revenue growth and a decline is the share price has really boosted the appeal, in my eyes. Shares jumped from $21 to $22 following the release of the results, as expectations have been reduced a great deal, but they have now fallen back to $19-20 again.

Compared to the start of the year, sales multiples have collapsed from about 20 times to 10 times, while growth is very strong and the company has a solid pipeline of extensions of CABOMETYX into other lines of cancer. The risk of this strategy is that Exelixis is pretty much a one-trick pony, at least for now. This could change a bit (in terms of indications, not product) if CABOMETYX were to be approved to treat advanced hepatocellular carcinoma as well, as the regulatory submission for that has been recently filed.

As noted above, the company furthermore earned about $0.10 per share this quarter without taking into account collaboration revenues, as quarterly costs came in at $96 million. With total costs seen at $430-460 million this year, this suggests a $110-120 million quarterly run rate in costs for the remaining three quarters each. While that is up $20 million compared to Q1, I do think it is fair to say that this could be made up for by increasing revenues, making a 4 x $0.10 = $0.40 per share in realistic earnings the absolute minimum this year.

The pick-up in growth means that the company is rapidly on track to achieve a billion in sales again. After all, sales have already surpassed the half billion mark, as sequential revenue growth between Q4 of 2017 and the recent quarter already adds about $150 million in annual sales. If the blockbuster status could indeed be achieved by 2019/2020, a current $6 billion valuation looks relatively modest, as I see no reason why margins of 30-40% could not be achievable at that point in time.

Averaging Down

I bought a small speculative position in January – of course, way too early. Fortunately, the position was just a fifth of my targeted position, as I am aggressively lowering my average costs by buying another 50% of my targeted position at these levels, lowering my average cost to about $22.

The fact that CABOMETYX is growing market share and shows these very healthy trends is encouraging, allowing for growing profits even as R&D budgets are creeping up. While management did not want to break down the increase in sequential sales line by line or indication by indication, it seems evident from commentary on the call that “organic” growth is showing up again after sales were flat between Q3 and Q4. In fact, not all growth can be attributed to wider indication approvals.

While there are still a few unknowns about the pick-up in CABOMETYX, as well as usual pipeline uncertainty of course, I am comfortable that the company can earn $0.50 per share this year, ex-royalties, while it steps up R&D efforts in a big way. Hence, I am willing to more than double down at these levels, mostly because of strong market share gains and continued near-term triggers to boost sales growth, cash flow generation and opportunities to add to the pipeline.

Please subscribe to Value In Corporate Events – Marketplace Checkout to obtain premium research on all the latest IPOs, M&A activity and other corporate events. Reviews of situations will be made upon request!

Disclosure: I am/we are long EXEL.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

SeekingAlpha

Best Warren Buffett Stocks To Buy Right Now

March has brought madness to airline stocks, including United Continental Holdings (UAL), Delta Air Lines (DAL), and American Airlines (AAL). But the recent pullbacks aren’t a buying opportunity, say Imperial Michael Derchin and Adam Hackel.

Agence France-Presse/Getty Images

I recommended United Continental on Nov. 19, the week that Warren Buffett’s Berkshire Hathaway (BRK.B) placed a bet on the group. And while the recommendation had been looking good until this week, when United Continental said it would be expanding capacity. That caused its shares to drop shares to drop 6.9% this week–and my bet to become a loser with a 1.4% drop since I recommended it.

So should you hang on to your airline shares? Not to hear Imperial’s Derchin and Hackel tell it:

While the airline stocks have pulled back recently, coming off a choppy 1Q17, we have In-Line ratings on the Big 3 (American Airlines [AAL], Delta Air Lines [DAL] and United Continental [UAL]), as well as on Alaska Air Group (ALK)…

Best Warren Buffett Stocks To Buy Right Now: Exelixis, Inc.(EXEL)

Advisors’ Opinion:

  • [By Dan Caplinger]

    Wall Street had another good session on Thursday, with further gains for major markets as benchmarks like the Russell 2000 index of small-cap stocks flirted with record highs. A favorable reading from the consumer price index showed only modest growth in prices, and the idea that inflation remains in check led market participants to believe that the Federal Reserve won’t have to speed up its efforts to return short-term interest rates to more normal levels. Yet even with the overall market picking up ground, some companies had bad news that weighed on their share prices. Booking Holdings (NASDAQ:BKNG), Exelixis (NASDAQ:EXEL), and L Brands (NYSE:LB) were among the worst performers on the day. Here’s why they did so poorly.

  • [By Joseph Griffin]

    Exelixis (NASDAQ:EXEL) – Equities researchers at Oppenheimer raised their Q2 2018 earnings per share (EPS) estimates for Exelixis in a report issued on Wednesday, May 2nd. Oppenheimer analyst L. Cann now forecasts that the biotechnology company will post earnings of $0.11 per share for the quarter, up from their prior forecast of $0.09. Oppenheimer currently has a “Outperform” rating and a $40.00 target price on the stock. Oppenheimer also issued estimates for Exelixis’ Q3 2018 earnings at $0.13 EPS, Q4 2018 earnings at $0.14 EPS and FY2018 earnings at $0.74 EPS.

  • [By Todd Campbell]

    Technology stocks are staples in growth portfolios because of their eye-popping revenue growth, but technology isn’t the only sector of the stock market that boasts fast-growing companies. For example, many healthcare stocks are growing at rates that Silicon Valley would envy. In fact, Foundation Medicine (NASDAQ:FMI), Exelixis Corp (NASDAQ:EXEL), and Teladoc (NYSE:TDOC) all reported year-over-year sales growth north of 100% in first-quarter 2018.

Best Warren Buffett Stocks To Buy Right Now: Illinois Tool Works Inc.(ITW)

Advisors’ Opinion:

  • [By Lisa Levin] Companies Reporting Before The Bell
    General Motors Company (NYSE: GM) is projected to report quarterly earnings at $1.24 per share on revenue of $34.66 billion.
    Bristol-Myers Squibb Company (NYSE: BMY) is estimated to report quarterly earnings at $0.85 per share on revenue of $5.24 billion.
    United Parcel Service, Inc. (NYSE: UPS) is expected to report quarterly earnings at $1.55 per share on revenue of $16.44 billion.
    Time Warner Inc. (NYSE: TWX) is projected to report quarterly earnings at $1.74 per share on revenue of $7.91 billion.
    ConocoPhillips (NYSE: COP) is expected to report quarterly earnings at $0.74 per share on revenue of $8.81 billion.
    PepsiCo, Inc. (NYSE: PEP) is expected to report quarterly earnings at $0.93 per share on revenue of $12.4 billion.
    American Airlines Group Inc. (NASDAQ: AAL) is estimated to report quarterly earnings at $0.72 per share on revenue of $10.42 billion.
    Southwest Airlines Co (NYSE: LUV) is expected to report quarterly earnings at $0.74 per share on revenue of $5.01 billion.
    Fiat Chrysler Automobiles N.V. (NYSE: FCAU) is estimated to report quarterly earnings at $0.8 per share on revenue of $34.52 billion.
    Union Pacific Corporation (NYSE: UNP) is projected to report quarterly earnings at $1.66 per share on revenue of $5.38 billion.
    D.R. Horton, Inc. (NYSE: DHI) is expected to report quarterly earnings at $0.85 per share on revenue of $3.76 billion.
    The Hershey Company (NYSE: HSY) is estimated to report quarterly earnings at $1.4 per share on revenue of $1.94 billion.
    Praxair, Inc. (NYSE: PX) is expected to report quarterly earnings at $1.56 per share on revenue of $2.94 billion.
    Altria Group, Inc. (NYSE: MO) is projected to report quarterly earnings at $0.92 per share on revenue of $4.63 billion.
    Shire plc (NASDAQ: SHPG) is estimated to report quarterly earnings at $3.54 per share on revenue of $3.72 billion.
    Oshkosh Corporation (NYSE: OSK) is projected to report quarter
  • [By ]

    Illinois Tools Works (ITW) shares fell after the company’s earnings report, but Cramer and the AAP team see it as an opportunity to buy more shares. Find out what they’re telling their investment club members and get in on the conversation with a free trial subscription to Action Alerts PLUS.

  • [By ]

    Illinois Tool Works Inc. (ITW)  fell on Thursday, April 26, after reporting weaker-than-expected results in its automotive segment and organic growth even as its first-quarter earnings exceeded expectations.

  • [By ]

    Illinois Tools Works (ITW) shares fell after the company’s earnings report, but Cramer and the AAP team see it as an opportunity to buy more shares. Find out what they’re telling their investment club members and get in on the conversation with a free trial subscription to Action Alerts PLUS.

  • [By ]

    Illinois Tools Works (ITW) shares fell after the company’s earnings report, but Cramer and the AAP team see it as an opportunity to buy more shares. Find out what they’re telling their investment club members and get in on the conversation with a free trial subscription to Action Alerts PLUS.

  • [By ]

    Illinois Tool Works (ITW) : “You don’t have to worry. This one is good. You shouldn’t be a seller.”

    PetMed Express (PETS) : “No, no, no, no. When we want pet drugs, we want Idexx Laboratories (IDXX) .”

Best Warren Buffett Stocks To Buy Right Now: Brandywine Realty Trust(BDN)

Advisors’ Opinion:

  • [By Max Byerly]

    ILLEGAL ACTIVITY WARNING: “Brandywine Realty Trust (BDN) Issues FY18 Earnings Guidance” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3371791/brandywine-realty-trust-bdn-issues-fy18-earnings-guidance.html.

Best Warren Buffett Stocks To Buy Right Now: Grifols, S.A.(GRFS)

Advisors’ Opinion:

  • [By Max Byerly]

    Financial Gravity Companies Inc. raised its stake in shares of Grifols (NASDAQ:GRFS) by 264.0% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 13,862 shares of the biotechnology company’s stock after purchasing an additional 10,054 shares during the quarter. Financial Gravity Companies Inc.’s holdings in Grifols were worth $282,000 as of its most recent filing with the SEC.

  • [By Shane Hupp]

    Grifols (NASDAQ:GRFS) was upgraded by equities researchers at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.

Best Warren Buffett Stocks To Buy Right Now: Dynagas LNG Partners LP(DLNG)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Dynagas LNG Partners (NYSE:DLNG) will post its quarterly earnings results after the market closes on Wednesday, May 16th. Analysts expect Dynagas LNG Partners to post earnings of $0.17 per share for the quarter.

  • [By Lisa Levin]

    Dynagas LNG Partners LP (NYSE: DLNG) shares dropped 12 percent to $9.33 after the company lowered its quarterly distribution to $0.25 per common unit from $0.4225 per common unit.

  • [By Lisa Levin]

    Dynagas LNG Partners LP (NYSE: DLNG) shares dropped 12 percent to $9.30 after the company lowered its quarterly distribution to $0.25 per common unit from $0.4225 per common unit.

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Valeritas Holdings Inc (NASDAQ: VLRX) fell 25.9 percent to $1.89 in pre-market trading. Valeritas priced its 13.7 million share offering at $1.75 per share.
    Zealand Pharma A/S (NASDAQ: ZEAL) fell 6.5 percent to $15.30 in pre-market trading after rising 9.80 percent on Monday.
    Dynagas LNG Partners LP (NYSE: DLNG) fell 5.1 percent to $9.00 in pre-market trading after slipping 1.15 percent on Monday.
    Incyte Corporation (NASDAQ: INCY) fell 5 percent to $64.80 in pre-market trading. Lilly and Incyte disclosed that the FDA Advisory Committee recommended approval of baricitinib 2mg, but not 4mg, for the treatment of moderately-to-severely active RAI.
    Casa Systems, Inc. (NASDAQ: CASA) fell 4.7 percent to $28.40 in pre-market trading after announcing a 7.35 million share common stock offering.
    Assured Guaranty Ltd. (NYSE: AGO) shares fell 4.5 percent to $34.30 in pre-market trading. The founder and president of Greenlight Capital talked about a short idea in Assured Guaranty, saying pre-tax income is likely to "collapse." He also highlighted Assured Guaranty insured $12.2 billion in below-investment grade bonds.
    The St. Joe Company (NYSE: JOE) shares fell 4 percent to $17.30 in pre-market trading.
    Masco Corporation (NYSE: MAS) shares fell 3.4 percent to $38.10 in pre-market trading

Best Warren Buffett Stocks To Buy Right Now: Intrexon Corporation(XON)

Advisors’ Opinion:

  • [By Todd Campbell]

    After the company reported disappointing first-quarter financial results, including worse-than-expected revenue performance, shares in Intrexon Corp.(NYSE:XON) were down by 20% at 3:15 p.m. EDT Friday.

  • [By Peter Graham]

    Small cap synthetic biology Intrexon Corp (NYSE: XON) has elevated short interest of 33.93% according to Highshortinterest.com. Intrexon Corp says itspowering the Bioindustrial Revolution with Better DNA⒙to create biologically-based products that improve the quality of life and the health of the planet. The Companysintegrated technology suite provides its partners across diverse markets with industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function and performance of living cells.

  • [By Dan Caplinger]

    Friday was a relatively quiet day on Wall Street, with major market benchmarks finishing narrowly mixed for the session. Weekly gains were still substantial for the indexes, however, as investors grew confident that the economy is walking the fine line between avoiding a recession and growing so fast that it spurs the Federal Reserve to tighten monetary policy aggressively. Yet even though most stocks held up well, some individual companies had bad news that sent their shares lower. Ultra Petroleum (NASDAQ:UPL), Intrexon (NYSE:XON), and News Corp. (NASDAQ:NWSA) were among the worst performers on the day. Here’s why they did so poorly.

Top Undervalued Stocks For 2018

We initiate a BUY rating on ATN International, Inc. (NASDAQ:ATNI), and our target price is $74.9. ATNI is an expanding company investing worldwide both in telecommunications and renewable energy industries. Its international and multi-industrial investing strategies successfully overcome the decline in U.S. telecommunications business, which ensures a stable growth rate for the company. The stable growth and strong financial capability in turn enable the company for further investments. Overall, we think the stock price is currently undervalued.

Company Highlights

(1) ATNI has made two acquisitions to strengthen its presence in the Caribbean and has started a large-scale solar project in India. These new ventures should enable the company to generate a new source of free cash flow after its prediction of breakeven by the first half of 2017.

(2) The U.S. telecom segment is shrinking due to lower wholesale roaming data rate, partially offset by an increase in data volume. We don’t see rapid growth in this segment.

Top Undervalued Stocks For 2018: NTT DOCOMO, Inc(DCM)

Advisors’ Opinion:

  • [By Logan Wallace]

    Bank of Hawaii bought a new position in NTT Docomo Inc (NYSE:DCM) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 8,664 shares of the technology company’s stock, valued at approximately $222,000.

Top Undervalued Stocks For 2018: ON Semiconductor Corporation(ON)

Advisors’ Opinion:

  • [By ]

    Though concerns have been raised that the analog and MCU markets are at risk of seeing an inventory correction (they haven’t had a major one in a while), given signs of excessive ordering and stretched lead times, TI and STMicro’s numbers suggest conditions remain good for now. That’s particularly true in industrial and auto markets where trends such as factory automation, ADAS adoption and electric/hybrid car sales are boosting chip demand. Several other analog/MCU firms, including Microchip (MCHP) , ON Semiconductor (ON) , Maxim Integrated (MXIM) and NXP Semiconductors (NXPI) , will be reporting soon.

  • [By Lee Jackson]

    Aggressive accounts may want to look at this smaller cap play. ON Semiconductor Corp. (NASDAQ: ON) is a vendor of analog power management, analog signal conditioning, standard logic integrated circuits and discrete chips into the automotive, communications, computing, consumer, industrial and medical applications. The company is in the midst of a transformation from a seller of commodity discrete chips into higher value added analog integrated circuits, both through organic growth and acquisitions.

Top Undervalued Stocks For 2018: Exelixis, Inc.(EXEL)

Advisors’ Opinion:

  • [By ]

    Exelixis (EXEL) : “Biotechs are not working so I’m not going to recommend it.”

    Moneygram (MGI) : “No, you need quality and this one doesn’t have it.”

  • [By Brian Orelli]

    After a disappointing fourth quarter, Exelixis (NASDAQ:EXEL) reaccelerated growth in the first quarter, bolstered by a new approval for Cabometyx in previously untreated advanced renal cell carcinoma (RCC), also known as kidney cancer.

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    MDC Partners Inc. (NASDAQ: MDCA) fell 23.4 percent to $5.25 in pre-market trading after a first-quarter earnings miss.
    Hudson Technologies Inc. (NASDAQ: HDSN) shares fell 15.1 percent to $3.48 in pre-market trading after the company reported downbeat Q1 earnings.
    Nuance Communications, Inc. (NASDAQ: NUAN) fell 14 percent to $13.15 in pre-market trading after the company posted downbeat Q2 earnings and lowered FY18 organic growth guidance.
    Myomo, Inc. (NYSE: MYO) fell 13.2 percent to $3.10 in pre-market trading after reporting downbeat quarterly results.
    Rowan Companies plc (NYSE: RDC) shares fell 10.7 percent to $14.13 in pre-market trading after climbing 8.50 percent on Wednesday.
    BT Group plc (NYSE: BT) fell 9 percent to $14.80 in pre-market trading after the company reported Q4 results and announced plans to cut 13,000 jobs over the next three years.
    Exelixis, Inc. (NASDAQ: EXEL) fell 8.3 percent to $19.90 in pre-market trading after the company disclosed that IMblaze370 Phase 3 pivotal trial of atezolizumab and cobimetinib in patients with heavily pretreated locally advanced or metastatic colorectal cancer did not meet primary endpoint.
    Infinera Corporation (NASDAQ: INFN) fell 8.2 percent to $10.80 in pre-market trading after reporting Q1 results.
    Synaptics, Incorporated (NASDAQ: SYNA) shares fell 7.4 percent to $43.00 in pre-market trading. Synaptics reported better-than-expected earnings for its third quarter, while sales missed estimates.
    Randgold Resources Limited (NASDAQ: GOLD) shares fell 7.4 percent to $76.23 in pre-market trading after reporting Q1 earnings.
    Integra LifeSciences Holdings Corporation (NASDAQ: IART) shares fell 7 percent to $59.36 in pre-market trading. Integra LifeSciences priced its 5.25 million share public offering of common stock at $58.50 per share.
    Array BioPharma Inc. (NASDAQ: ARRY) shares fell 6.9 percent to $12.75 in pre-m

  • [By Joseph Griffin]

    Exelixis (NASDAQ:EXEL) – Equities researchers at Oppenheimer raised their Q2 2018 earnings per share (EPS) estimates for Exelixis in a report issued on Wednesday, May 2nd. Oppenheimer analyst L. Cann now forecasts that the biotechnology company will post earnings of $0.11 per share for the quarter, up from their prior forecast of $0.09. Oppenheimer currently has a “Outperform” rating and a $40.00 target price on the stock. Oppenheimer also issued estimates for Exelixis’ Q3 2018 earnings at $0.13 EPS, Q4 2018 earnings at $0.14 EPS and FY2018 earnings at $0.74 EPS.

Top Undervalued Stocks For 2018: Insmed, Inc.(INSM)

Advisors’ Opinion:

  • [By Jon C. Ogg]

    Insmed Inc. (NASDAQ: INSM) was raised to Outperform from Neutral at Credit Suisse.

    Lululemon Athletica Inc. (NASDAQ: LULU) was downgraded to Hold from Buy at Needham, based on the run-up in shares and on a harder earnings comparison that will be harder to beat. Lululemon was up 1% at $96.31 but was down 2% at $94.30 on Monday. It had a consensus target price of $89.93.

  • [By Lisa Levin] Gainers
    Check-Cap Ltd. (NASDAQ: CHEK) shares rose 78.82 percent to close at $7.26 on Monday.
    GEE Group, Inc. (NYSE: JOB) shares jumped 18 percent to close at $2.36.
    McDermott International, Inc. (NYSE: MDR) climbed 15.7 percent to close at $7.00 after the UK-based offshore oil service company Subsea 7 made an unsolicited bid to buy McDermott for $7 per share. However, the acquisition offer is contingent on McDermot terminating its pending merger with Chicago Bridge & Iron Company.
    Foresight Autonomous Holdings Ltd (NASDAQ: FRSX) gained 17.21 percent to close at $3.61.
    Stars Group Inc. (NASDAQ: TSG) rose 14.16 percent to close at $33.45. Stars Group Inc (NASDAQ: TSG) announced plans to acquire Sky Betting & Gaming for $4.7 billion.
    China Internet Nationwide Financial Services Inc. (NASDAQ: CIFS) shares jumped 12.79 percent to close at $25.58.
    Nautilus, Inc. (NYSE: NLS) shares gained 11.52 percent to close at $15.00. Nautilus is expected to release Q1 results on May 7, 2018. Craig-Hallum initiated coverage on Nautilus with a Buy rating and a $19.00 price target.
    Box, Inc. (NYSE: BOX) rose 10.94 percent to close at $22.91.
    Insmed Incorporated (NASDAQ: INSM) shares rose 10.76 percent to close at $26.05. Credit Suisse upgraded Insmed from Neutral to Outperform.
    NextDecade Corporation (NASDAQ: NEXT) shares rose 10.02 percent to close at $6.48.
    Helios and Matheson Analytics Inc. (NASDAQ: HMNY) shares gained 8.37 percent to close at $2.46 on Monday after falling 10.98 percent on Friday.
    Cambium Learning Group, Inc. (NASDAQ: ABCD) shares gained 7.81 percent to close at $11.11.
    Vectren Corporation (NYSE: VVC) shares rose 7.26 percent to close at $70.31. CenterPoint Energy, Inc. (NYSE: CNP) announced plans to acquire Vectren for $72 per share in cash.
    Tennant Company (NYSE: TNC) rose 6.66 percent to close at $74.45 after the company posted upbeat Q1 results and raised its FY18 earnings outlook.
    Hanesbrands Inc.
  • [By Lisa Levin]

    Insmed Incorporated (NASDAQ: INSM) shares were also up, gaining 9 percent to $25.57. Credit Suisse upgraded Insmed from Neutral to Outperform.

    Equities Trading DOWN

Top Undervalued Stocks For 2018: American Electric Power Company, Inc.(AEP)

Advisors’ Opinion:

  • [By ]

    In an “Executive Decision” segment, Cramer checked in with Nick Akins, chairman, president and CEO of American Electric Power (AEP) , the utility that just posted a two-cents-a-share earnings miss, but reiterated their full-year guidance. Shares of American Electric Power are down 5.1% for the year but yield 3.6%.

  • [By Chris Lange]

    American Electric Power Company, Inc. (NYSE: AEP) shares were recently up 2.5% at $64.93, with a 52-week range of $62.69 to $78.07 and a consensus price target of $74.00.

  • [By Lisa Levin] Companies Reporting Before The Bell
    General Motors Company (NYSE: GM) is projected to report quarterly earnings at $1.24 per share on revenue of $34.66 billion.
    Bristol-Myers Squibb Company (NYSE: BMY) is estimated to report quarterly earnings at $0.85 per share on revenue of $5.24 billion.
    United Parcel Service, Inc. (NYSE: UPS) is expected to report quarterly earnings at $1.55 per share on revenue of $16.44 billion.
    Time Warner Inc. (NYSE: TWX) is projected to report quarterly earnings at $1.74 per share on revenue of $7.91 billion.
    ConocoPhillips (NYSE: COP) is expected to report quarterly earnings at $0.74 per share on revenue of $8.81 billion.
    PepsiCo, Inc. (NYSE: PEP) is expected to report quarterly earnings at $0.93 per share on revenue of $12.4 billion.
    American Airlines Group Inc. (NASDAQ: AAL) is estimated to report quarterly earnings at $0.72 per share on revenue of $10.42 billion.
    Southwest Airlines Co (NYSE: LUV) is expected to report quarterly earnings at $0.74 per share on revenue of $5.01 billion.
    Fiat Chrysler Automobiles N.V. (NYSE: FCAU) is estimated to report quarterly earnings at $0.8 per share on revenue of $34.52 billion.
    Union Pacific Corporation (NYSE: UNP) is projected to report quarterly earnings at $1.66 per share on revenue of $5.38 billion.
    D.R. Horton, Inc. (NYSE: DHI) is expected to report quarterly earnings at $0.85 per share on revenue of $3.76 billion.
    The Hershey Company (NYSE: HSY) is estimated to report quarterly earnings at $1.4 per share on revenue of $1.94 billion.
    Praxair, Inc. (NYSE: PX) is expected to report quarterly earnings at $1.56 per share on revenue of $2.94 billion.
    Altria Group, Inc. (NYSE: MO) is projected to report quarterly earnings at $0.92 per share on revenue of $4.63 billion.
    Shire plc (NASDAQ: SHPG) is estimated to report quarterly earnings at $3.54 per share on revenue of $3.72 billion.
    Oshkosh Corporation (NYSE: OSK) is projected to report quarter

Wedbush Securities Inc. Purchases Shares of 14,215 Exelixis (EXEL)

Wedbush Securities Inc. purchased a new position in shares of Exelixis (NASDAQ:EXEL) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 14,215 shares of the biotechnology company’s stock, valued at approximately $315,000.

A number of other institutional investors also recently made changes to their positions in the stock. Public Employees Retirement Association of Colorado grew its holdings in Exelixis by 3.5% during the fourth quarter. Public Employees Retirement Association of Colorado now owns 53,942 shares of the biotechnology company’s stock worth $1,640,000 after buying an additional 1,840 shares in the last quarter. Amalgamated Bank grew its holdings in Exelixis by 5.7% during the fourth quarter. Amalgamated Bank now owns 57,785 shares of the biotechnology company’s stock worth $1,757,000 after buying an additional 3,141 shares in the last quarter. Raymond James Financial Services Advisors Inc. grew its holdings in Exelixis by 41.7% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 13,817 shares of the biotechnology company’s stock worth $420,000 after buying an additional 4,067 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Exelixis by 29.8% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 21,019 shares of the biotechnology company’s stock worth $639,000 after buying an additional 4,820 shares in the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. grew its stake in Exelixis by 18.8% in the 4th quarter. Ladenburg Thalmann Financial Services Inc. now owns 31,612 shares of the biotechnology company’s stock valued at $961,000 after purchasing an additional 5,005 shares during the period. Institutional investors and hedge funds own 80.57% of the company’s stock.

Get Exelixis alerts:

EXEL stock opened at $22.21 on Tuesday. The firm has a market cap of $6.66 billion, a PE ratio of 43.55 and a beta of 2.10. Exelixis has a fifty-two week low of $18.03 and a fifty-two week high of $32.50.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Monday, February 26th. The biotechnology company reported $0.12 earnings per share for the quarter, hitting the consensus estimate of $0.12. The company had revenue of $120.10 million during the quarter, compared to the consensus estimate of $120.25 million. Exelixis had a return on equity of 77.39% and a net margin of 43.39%. The firm’s quarterly revenue was up 54.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.12 EPS. research analysts forecast that Exelixis will post 0.8 earnings per share for the current fiscal year.

A number of research analysts have issued reports on the company. BidaskClub upgraded Exelixis from a “hold” rating to a “buy” rating in a research note on Thursday, January 25th. Oppenheimer upgraded Exelixis from a “market perform” rating to an “outperform” rating and set a $40.00 price objective for the company in a research note on Tuesday, February 27th. Cann upgraded Exelixis from a “market perform” rating to an “outperform” rating and set a $40.00 price objective for the company in a research note on Tuesday, February 27th. They noted that the move was a valuation call. UBS upgraded Exelixis from a “market perform” rating to an “outperform” rating in a research note on Tuesday, February 27th. Finally, Stifel Nicolaus upped their price objective on Exelixis from $29.00 to $30.00 and gave the company a “hold” rating in a research note on Tuesday, February 27th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and nine have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $34.00.

In other news, Director George Poste sold 15,000 shares of the stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $26.26, for a total transaction of $393,900.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Patrick J. Haley sold 27,549 shares of the stock in a transaction on Monday, May 7th. The stock was sold at an average price of $22.17, for a total value of $610,761.33. The disclosure for this sale can be found here. Insiders have sold a total of 307,627 shares of company stock valued at $7,068,320 in the last quarter. 4.80% of the stock is owned by corporate insiders.

About Exelixis

Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Exelixis (EXEL) to Post Q2 2018 Earnings of $0.11 Per Share, Oppenheimer Forecasts

Exelixis (NASDAQ:EXEL) – Equities researchers at Oppenheimer raised their Q2 2018 earnings per share (EPS) estimates for Exelixis in a report issued on Wednesday, May 2nd. Oppenheimer analyst L. Cann now forecasts that the biotechnology company will post earnings of $0.11 per share for the quarter, up from their prior forecast of $0.09. Oppenheimer currently has a “Outperform” rating and a $40.00 target price on the stock. Oppenheimer also issued estimates for Exelixis’ Q3 2018 earnings at $0.13 EPS, Q4 2018 earnings at $0.14 EPS and FY2018 earnings at $0.74 EPS.

Get Exelixis alerts:

EXEL has been the topic of several other research reports. BidaskClub cut Exelixis from a “buy” rating to a “hold” rating in a report on Thursday, March 1st. Cann restated a “buy” rating and set a $40.00 price objective on shares of Exelixis in a report on Thursday, March 8th. William Blair restated a “buy” rating on shares of Exelixis in a report on Wednesday, April 11th. Stifel Nicolaus decreased their price objective on Exelixis from $30.00 to $29.00 and set a “hold” rating on the stock in a report on Thursday, May 3rd. Finally, Zacks Investment Research upgraded Exelixis from a “sell” rating to a “hold” rating in a report on Monday, April 30th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and nine have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $34.00.

EXEL stock opened at $22.21 on Monday. Exelixis has a 52-week low of $18.03 and a 52-week high of $32.50. The firm has a market cap of $6.66 billion, a PE ratio of 43.55 and a beta of 2.10.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Monday, February 26th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.12. Exelixis had a return on equity of 77.39% and a net margin of 43.39%. The business had revenue of $120.10 million for the quarter, compared to analysts’ expectations of $120.25 million. During the same quarter last year, the firm earned $0.12 earnings per share. The business’s revenue was up 54.8% on a year-over-year basis.

In related news, Director Alan M. Garber sold 15,000 shares of the stock in a transaction on Monday, April 16th. The stock was sold at an average price of $20.25, for a total value of $303,750.00. Following the transaction, the director now directly owns 76,329 shares of the company’s stock, valued at approximately $1,545,662.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Patrick J. Haley sold 12,549 shares of the stock in a transaction on Friday, May 4th. The stock was sold at an average price of $22.38, for a total value of $280,846.62. The disclosure for this sale can be found here. Insiders sold a total of 307,627 shares of company stock worth $7,068,320 over the last ninety days. Corporate insiders own 4.80% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the business. Public Employees Retirement Association of Colorado raised its position in Exelixis by 3.5% in the fourth quarter. Public Employees Retirement Association of Colorado now owns 53,942 shares of the biotechnology company’s stock valued at $1,640,000 after purchasing an additional 1,840 shares during the period. Amalgamated Bank raised its position in Exelixis by 5.7% in the fourth quarter. Amalgamated Bank now owns 57,785 shares of the biotechnology company’s stock valued at $1,757,000 after purchasing an additional 3,141 shares during the period. Raymond James Financial Services Advisors Inc. raised its position in Exelixis by 41.7% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 13,817 shares of the biotechnology company’s stock valued at $420,000 after purchasing an additional 4,067 shares during the period. Meeder Asset Management Inc. raised its position in Exelixis by 83.4% in the first quarter. Meeder Asset Management Inc. now owns 9,887 shares of the biotechnology company’s stock valued at $218,000 after purchasing an additional 4,495 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in Exelixis by 29.8% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 21,019 shares of the biotechnology company’s stock valued at $639,000 after purchasing an additional 4,820 shares during the period. 80.57% of the stock is currently owned by institutional investors.

About Exelixis

Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Earnings History and Estimates for Exelixis (NASDAQ:EXEL)